



Australian Government

**Department of Health
and Aged Care**

Pharmaceutical Benefits Scheme

Expenditure and Prescriptions Report

1 July 2023 to 30 June 2024

*PBS Analytics and Strategic Insight Section
Pricing and PBS Policy Branch
Technology Assessment and Access Division*









This publication and previous editions can be accessed via the internet:
<http://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries or feedback to:

Surface mail: Director
PBS Analytics and Strategic Insight Section
Pricing and PBS Policy Branch, MDP 900
Department of Health and Aged Care
GPO Box 9848 Canberra ACT 2601

E-mail: pbsstats@health.gov.au

Expenditure and Prescription Snapshot - 2023-24

	<p>Government expenditure was \$17.7 billion for the supply of medicines.</p>	<p>This represents 91.6% of total medicine costs and was up 6.1% from 2022-23.</p>
	<p>Patients contributed \$1.6 billion to the cost of their medicines.</p>	<p>This represents 8.4% of total medicine cost.</p>
	<p>226.5 million subsidised prescriptions¹ were dispensed.</p>	<p>The number of subsidised prescriptions increased by 1.5% compared to 2022-23.</p> <p>The average dispensed price² per PBS subsidised prescription was \$85.11 (up from \$81.71 in 2022-23).</p>
	<p>Concession card holders:</p> <ul style="list-style-type: none"> received 199.0 million (87.8%) subsidised prescriptions. accounted for \$10.8 billion (60.9%) of total Government expenditure on medicine. 	<p>Expenditure for this group was up from \$10.5 billion (62.6%) in 2022-23.</p> <p>The average dispensed price for concessional cardholders was \$58.93.</p> <p>The government contributed \$54.34 towards the cost of each concession cardholder medicine on average.</p>
	<p>General patients:</p> <ul style="list-style-type: none"> received 27.1 million (12.0%) of subsidised prescriptions accounted for \$6.8 billion (38.3%) of Government expenditure on medicine. 	<p>Expenditure for this group was up from \$6.2 billion (36.9%) in 2022-23.</p> <p>The average dispensed price for general patients³ was \$277.07.</p> <p>The government contributed \$250.60 towards the cost of each general patient medicine on average.</p>
	<p>930 different medicines were listed on the PBS as at 30 June 2024.</p>	<p>These medicines were spread across 5,164 brands.</p>

¹ Includes subsidised prescriptions for concessional cardholders, general patients, and from the Doctors' Bag.

² Patient payment plus Government benefit.

³ General patients hold a Medicare card only and are not concessional cardholders.

Key Statistics

This report details expenditure and prescriptions information relating to key elements of the Pharmaceutical Benefits Scheme. The information is presented on an expenditure (cash) basis for 2023-24, unless indicated otherwise. Data variables such as Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums⁴.

PBS Expenditure is classified into the following patient categories⁵.

Patient Category	Patient Co-payment Amount
General - Non-Safety Net (Ordinary)	\$31.60
General - Safety Net	\$7.70
Concessional - Non-Safety Net (Ordinary)	\$7.70
Concessional - Safety Net	\$0

Within the PBS, patients are categorised according to the cards that they hold when PBS benefits are supplied. General patients hold a Medicare card. Concessional patients hold a Medicare card and a: Pension Concession Card, Commonwealth Seniors Health Card, or a Health Care Card.

When patients and their family members spend a certain amount on PBS prescriptions (the safety net threshold amount) they can apply for a Safety Net Card and pay the reduced co-payment amount for their patient category for the remainder of the calendar year.

From 1 January 2024 the general patient safety net threshold amount was \$1,647.90 and the concessional safety net threshold amount was \$277.20.

⁴ The PBS subsidises up to the price of the lowest priced brand for generic equivalents (except where the lowest priced brand has, as part of its price, a therapeutic group premium). This means that consumers may have to pay extra for more expensive brands (those with a brand premium).


Consumers may have to pay extra for more expensive drugs (those with a therapeutic group premium).

⁵ The Doctors' Bag is an additional patient category, where medicines are provided to patients for emergency use for free by an approved supplier.

Patients


Concessional patients accounted for the majority (88%) of prescriptions in 2024, but only 39% of Government expenditure.

Chart 1: Prescriptions and government expenditure by patient type 2023-24



The total cost of a medicine is the combined patient cost plus government cost. The average medicine cost is total cost (Patient and Government cost) divided by total PBS subsidised prescriptions. This value gives insight into the average total cost of a single PBS medicine, and it varies between different patient categories. **The average total cost of medicines for concessional patients who accessed the Safety Net was six times less than the average total cost of medicines for general patients who did not access the Safety Net.**

Chart 2: Average medicine cost by patient category 2023-24




Demographics

Over 178.6 million PBS prescriptions were dispensed to females and 152.5 million to males in 2023-24⁶. These figures correspond to government expenditure (for over-copayment contributions) of \$9.0 billion and \$8.6 billion respectively.

The number of PBS prescriptions dispensed increases as patient age increases. Most prescriptions (209.0 million or 63.1%) were dispensed to patients in the 60+ years-of-age group (Chart 3). All other age groups accounted for 122.1 million of the total 331.0 million subsidised and under-copayment prescriptions.

- The cost to government for patients aged 60+ years amounted to \$10.5 billion (59.6%) of total government spending on medicines (\$17.6 billion).

Chart 3: Prescriptions and government cost by gender and patient age, 2023-24




Notes: Approximately 1.1% of all prescriptions are excluded due to unknown patient demographic details. Reported gender in the PBS Online Claims Data is sourced from Services Australia. Department of Health and Aged Care does not have access to Medicare personal records.

⁶ PBS subsidised and under co-payment prescriptions (excludes Doctors' Bag). These exclude approximately 1.1% of all prescriptions due to unknown patient demographic details.

Geographic distribution


The distribution of PBS subsidised script volumes corresponds to the cost to government. New South Wales, Victoria and Queensland had the greatest script volume and expenditure in absolute value terms.

Chart 4: Prescriptions and government cost by State/Territory, 2023-24



On a per capita basis Tasmania and South Australia had the largest number of prescriptions and government expenditure.

Chart 5: Per capita prescriptions and government cost by State/Territory



- The Northern Territory and Australian Capital Territory had the lowest script volume and expenditure in both absolute value and per capita basis.
- The national average number of prescriptions was 8.4 per capita.
- The national average government cost was \$653.29 per capita.

Recent patient cost saving measures

There are three key recent PBS Budget measures that operate to ensure that Australians have access to affordable medicines.

General Patient Co-Payment reduction

General Patient Co-Payment was lowered from \$42.50 to \$30.00 per PBS subsidised prescription from 1 January 2023 and is estimated to save patients over \$280 million annually (Table 1).

- Patient co-payment and Safety Net thresholds are adjusted on 1 January each year in line with increases in the Consumer Price Index (CPI) and from 1 January 2024 the general patient co-payment amount is \$31.60.
- While the reduction to the general co-payment increased the number of scripts required to reach the general patient Safety Net threshold, it means total patient costs are lower.

Table 1: Number of general patients, number of subsidised (above co-payment) prescriptions, and estimated patient savings from the lower co-payment for 2023-24⁷

General Patient Count	Number of Subsidised Prescriptions	Estimated Patient Savings
4,116,252	22,292,305	\$283.4 million

60-Day Prescriptions

From 1 September 2023 patients with chronic, stable medical conditions can be prescribed and dispensed a 60-day supply of medicine (rather than a 30-day supply) for eligible PBS items which is estimated to save patients around \$54.4 million in 2023-24⁸.

- Patients with a Medicare card and a concession card receive 60 days' medication for the cost of 30 days, and only pay a single \$7.70 co-payment.
- Patients with a Medicare card but don't have a concession card who use medicines costing:
 - \$31.60 or more, receive 60 days' medication for the cost of 30 days, and only pay a single \$31.60 co-payment.
 - less than \$31.60, will not pay the same amount as for 30 days, but it will usually pay less than the cost for 60 days.
- 60-day prescriptions were introduced in three stages for certain medicines:
 - Stage 1 medicines started from 1 September 2023.
 - Stage 2 from 1 March 2024.
 - Stage 3 from 1 September 2024 (Table 2).
- A full list of eligible medicines and stages is at: <https://www.health.gov.au/cheaper-medicines/60-day-dispensing-pbs-medicines-and-current-item-codes>.

⁷ Notes and methodology regarding PBS Patient Co-Payment Reduction are at the Technical Notes.

⁸ Notes and methodology regarding 60-day prescriptions are at the Technical Notes.

Table 2: PBS prescription counts for stage 1 and 2 medicines dispensed via 30-day and 60-day prescriptions supplied for 1 September 2023 to 30 June 2024⁹. Stage 3 was implemented from 1 September 2024, and information is therefore not included in the 2023-24 report.

Stage	30-Day Prescriptions	60-Day Prescriptions	Total Prescriptions	60-Day %
Stage 1	87,131,129	8,241,065	95,372,194	8.6%
Stage 2	9,154,038	327,116	9,481,154	3.5%
Total	96,285,167	8,568,181	104,853,348	8.2%

Reduced Safety Net Threshold¹⁰

On 1 July 2022 the General and Concessional Safety Net Thresholds were lowered from \$1,542.10 to \$1,457.10 and \$326.40 to \$244.80 respectively, which is estimated to save patients in the order of \$200 million annually¹¹.

- The number of PBS prescriptions required to reach the Concessional Safety Net threshold was lowered from 48 to 36.

⁹ Data for 60-Day prescriptions are not available for the full 2023-24 financial year as Stage 1 medicines only became available from 1 September 2023. Data excludes Stage 3 medicines, as they were introduced in the 2024-25 financial year.

¹⁰ Per the Enactment of the Treasury Laws Amendment (Cost of Living Support and Other Measures) Bill 2022.


¹¹ Notes and methodology regarding estimated savings due to the reduced Safety Net threshold are at the Technical Notes.

Detailed information

Description		Page
Total Expenditure and Prescriptions - Overview		
Figure 1	PBS Expenditure and Prescription Volume, 2004-05 to 2023-24	1
Table 1(a)	PBS Expense - accrual, 2022-23 and 2023-24	2
Table 1(b)	PBS Section 100 Program expense - accrual, 2022-23 and 2023-24	2
Table 2(a)	PBS Prescriptions, 2022-23 and 2023-24	3
Table 2(b)	PBS Government Cost, 2022-23 and 2023-24	3
Table 2(c)	RPBS and PBS Subsidised Prescriptions for DVA patients, 2022-23 and 2023-24	3
Table 2(d)	RPBS and PBS Government Cost for DVA patients, 2022-23 and 2023-24	3
Subsidised Prescriptions		
Table 3(a)	PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2023-24	4
Table 3(b)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2023-24	4
Table 3(c)	PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2022-23 and 2023-24	4
Table 4	PBS Subsidised Prescriptions by Pharmacy State, 2023-24	5
Top Drugs/Medicines/Brands		
Table 5(a)	Top 50 PBS Drugs (by Active Ingredient) by Highest Government Cost, 2023-24	6
Table 5(b)	Top 50 PBS Drugs (by Active Ingredient) by Highest Subsidised Prescriptions, 2023-24	7
Table 5(c)	Top 25 PBS Antineoplastic Drugs (by Active Ingredient) by Highest Government Cost, 2023-24	8
Table 5(d)	Top 25 PBS Biological Products and Medicines by Highest Government Cost, 2023-24	8
Table 5(e)	Top 50 PBS Brands, excluding Efficient Funding of Chemotherapy (EFC) by Highest Government Cost, 2023-24	9
Table 5(f)	Top 50 PBS Brands (excluding EFC) by Highest Subsidised Prescriptions, 2023-24	10
Table 5(g)	Biosimilar Products and Medicines (excluding EFC) by Highest Government Cost, 2023-24	11
Table 6(a)	Top 50 PBS Drugs (by Active Ingredient) by Highest Total Prescription Volume, 2023-24	12
Table 6(b)	Top 10 PBS Drugs (by Active Ingredient) per age group and patient gender, by Highest Total Prescription Volume, 2023-24	13
Patient Demographics and Residential Aged Care Facilities (RACF)		
Figure 2	Total Government Cost by gender and age-groups, 2023-24	14
Figure 3	Total PBS prescriptions by gender and age-groups, 2023-24	15
Figure 4	PBS prescriptions dispensed in a Residential Aged Care Facility (RACF), 2023-24	16
Table 6(c)	PBS prescriptions per age group and patient gender, 2023-24	16
Table 6(d)	PBS prescriptions dispensed in a Residential Aged Care Facility, 2023-24	16
Table 6(e)	Top 10 PBS Drugs (Generic Name) by Highest Government Cost, dispensed in a Residential Aged Care Facility, 2023-24	17
Table 6(f)	Top 10 PBS Drugs (Generic Name) by Highest Prescriptions, dispensed in a Residential Aged Care Facility, 2023-24	17

Anatomical Therapeutic Classification (ATC) and Highest Changes		
Table 7	Top 50 ATC Level 2 Drug Groups by Highest Total Prescription Volume, 2023-24	18
Table 8	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2022-23 and 2023-24	19
Figure 5(a)	Percentages of subsidised prescriptions for ATC main groups, 2023-24	20
Figure 5(b)	Percentages of Government Cost for ATC main groups, 2023-24	21
Table 9(a)	Top 35 Drugs by Highest Change to Government Cost, 2022-23 and 2023-24	22
Table 9(b)	Top 35 Drugs by Highest Change to Subsidised Script Volume, 2022-23 and 2023-24	23
Table 10(a)	PBS Generic Prescriptions per ATC level 1, 2023-24	24
Table 10(b)	PBS Generic Prescriptions Percentage Share by ATC level 1, 2023-24	24
Formularies and Responsible Persons		
Table 11	PBS Prescriptions and Government Cost by Formulary, 2023-24	25
Table 12(a)	Top 20 Responsible Persons by Total Cost, 2023-24	26
Table 12(b)	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2023-24	27
Table 12(c)	Top 20 Responsible Persons by Total PBS Prescriptions, 2023-24	28
Approved Suppliers, Brand Premiums, and Electronic Prescriptions		
Table 13	Number of PBS Approved Suppliers, 30 June 2024	29
Table 14(a)	PBS Brand Premiums, 2023-24	29
Table 14(b)	Electronic PBS Prescriptions, 2023-24	29
PBS / Repatriation Pharmaceutical Benefits Scheme (RPBS)		
Table 15(a)	Table 15(a) PBS/RPBS prescriptions dispensed by Community Pharmacies, 2023-24	30
Table 15(b)	Table 15(b) PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2023-24	30
Table 16(a)	PBS/RPBS Medicines Supplied under Continued Dispensing by ATC Level 1 and Dispensing Pharmacy State, 2023-24	31
Table 16(b)	PBS/RPBS Continued Dispensing Medicines Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2023-24	31
Supplements and Appendices		
Supplement 1	Community Pharmacy Agreement (CPA) Expenses	
Table 17(a)	Remuneration for Community Pharmacies and Friendly Societies for PBS subsidised prescriptions, 2020-21 to 2023-24	32
Table 17(b)	Pharmacies Remuneration for PBS prescriptions by Formulary, 2020-21 to 2023-24	33
Table 18	CPA Professional Pharmacy Programs Expenditure, 2023-24	34
Table 19	Actual Costs of Major Components of CPA, 2023-24	35
Table 20	Community Services Obligation (CSO) Expenditure, 2023-24	35
Supplement 2	PBS Information Line Report, 2023-24	36
Supplement 3	National Diabetes Services Scheme (NDSS)	37
Appendix 1	Abbreviations	39
Appendix 2	Technical Notes	40

Figure 1: PBS Expenditure and Prescription Volume, 2004-05 to 2023-24
 Section 85 and Section 100 including Doctors' Bag and under co-payment prescriptions*



*Amendments to the Commonwealth of Australia National Health Act 1953 have been enacted that required approved suppliers of Pharmaceutical Benefits Scheme (PBS) medicines to provide the Australian Government, from 1 April 2012, with data on PBS prescriptions that are priced below the general copayment level (under copayment). Details of the legislation enacted on 23 November 2010 can be found in the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2010.

PBS Expenditure and Prescriptions 2023-24

Table 1(a): PBS Expense accrual, 2022-23 and 2023-24

Category	2022-23	Percentage of Total	2023-24	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$8,242,967,628	48.5%	\$8,569,256,355	47.6%	\$326,288,727	4.0%
Section 85 - General	\$3,675,234,739	21.6%	\$4,158,175,163	23.1%	\$482,940,424	13.1%
Doctors' Bag**	\$84,059,004	0.5%	\$133,586,768	0.7%	\$49,527,763	58.9%
Section 100*	\$4,971,448,827	29.3%	\$5,120,564,558	28.4%	\$149,115,730	3.0%
Safety Net Cards	\$19,242,896	0.1%	\$22,336,592	0.1%	\$3,093,696	16.1%
Total	\$16,992,953,095	100.0%	\$18,003,919,435	100.0%	\$1,010,966,340	5.9%
Total Including Revenue	\$12,341,307,185		\$12,671,374,977		\$330,067,791	2.7%

*Individual S100 programs are shown in Table 1(b).

**In 2022-23 dispensing of COVID-19 therapies MOLNUPIRAVIR and NIRMATRELVIR (&) RITONAVIR through Doctors' Bag cost the government over \$60m, in 2023-24 this cost over \$110m

Table 1(b): PBS Section 100 Programs expense accrual, 2022-23 and 2023-24

Category	2022-23	Percentage of Total	2023-24	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs	\$2,441,943,534	49.1%	\$2,386,300,078	46.6%	-\$55,643,455	-2.3%
Chemotherapy (EFC & Chemotherapy-related)	\$1,999,231,593	40.2%	\$2,293,136,731	44.8%	\$293,905,138	14.7%
In Vitro Fertilisation	\$161,479,146	3.2%	\$160,849,743	3.1%	-\$629,403	-0.4%
Opiate Dependence Treatment Program*	\$133,907,727	2.7%	\$30,593,124	0.6%	-\$103,314,603	-77.2%
Aboriginal Health Services (GST exclusive)	\$65,568,912	1.3%	\$73,974,778	1.4%	\$8,405,866	12.8%
Botulinum Toxin Program (incl. Dysport)	\$70,081,895	1.4%	\$72,467,223	1.4%	\$2,385,328	3.4%
Growth Hormone	\$35,403,949	0.7%	\$33,389,093	0.7%	-\$2,014,857	-5.7%
Paraplegic and Quadriplegic Program	\$127,939	0.0%	\$63,025	0.0%	-\$64,914	-50.7%
Medication Program for Homeless People	\$131,752	0.0%	\$148,594	0.0%	\$16,842	12.8%
Closing the Gap (CTG) PBS Co-payment Program	\$63,572,381	1.3%	\$69,642,169	1.4%	\$6,069,788	9.5%
Total	\$4,971,448,827	100.0%	\$5,120,564,558	100.0%	\$149,115,730	3.0%

Note:

Expense figures refer to payments made through the Services Australia and directly from the Department of Health and Aged Care Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on www.pbs.gov.au.

*On 1 July 2023, ODT medicines became part of the Section 100 Highly Specialised Drugs(HSD) Program (Community Access) arrangements. The Australian Government continued to pay pharmaceutical companies directly for ODT medicines supplied to authorised private ODT clinics and other non-PBS dosing sites (including GP clinics) for a transition period of 1 July 2023 to 30 June 2024

PBS Expenditure and Prescriptions 2023-24

Table 2(a): PBS Prescriptions, 2022-23 and 2023-24

Section 85 and S100, including Doctors' Bag and under co-payment prescriptions

Patient Category	2022-23		2023-24		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	127,927,542	57.3%	126,069,354	55.7%	-1,858,188	-1.5%
Concessional Safety Net	70,587,688	31.6%	72,885,129	32.2%	2,297,441	3.3%
Total Concessional	198,515,230	89.0%	198,954,483	87.8%	439,253	0.2%
General Non-Safety Net	21,024,711	9.4%	25,056,303	11.1%	4,031,592	19.2%
General Safety Net	3,225,443	1.4%	2,075,206	0.9%	-1,150,237	-35.7%
Total General	24,250,154	10.9%	27,131,509	12.0%	2,881,355	11.9%
Doctors' Bag	384,817	0.2%	422,617	0.2%	37,800	9.8%
Total (Over Co-payment)	223,150,201	100.0%	226,508,609	100.0%	3,358,408	1.5%
Under Co-payment	105,616,390		106,011,720		395,330	0.4%
Total (Over and Under Co-payment)	328,766,591		332,520,329		3,753,738	1.1%

Table 2(b): PBS Government Cost, 2022-23 and 2023-24

Section 85 and S100, including Doctors' Bag and excluding under co-payment prescriptions

Patient Category	2022-23		2023-24		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$7,352,983,770	44.0%	\$7,564,422,947	42.6%	\$211,439,176	2.9%
Concessional Safety Net	\$3,116,109,374	18.6%	\$3,247,695,209	18.3%	\$131,585,834	4.2%
Total Concessional	\$10,469,093,145	62.6%	\$10,812,118,155	60.9%	\$343,025,011	3.3%
General Non-Safety Net	\$5,975,293,773	35.7%	\$6,686,174,489	37.7%	\$710,880,716	11.9%
General Safety Net	\$193,515,679	1.2%	\$112,932,290	0.6%	-\$80,583,389	-41.6%
Total General	\$6,168,809,452	36.9%	\$6,799,106,780	38.3%	\$630,297,327	10.2%
Doctors' Bag*	\$80,189,516	0.5%	\$131,296,722	0.7%	\$51,107,205	63.7%
Total (Over Co-payment)	\$16,718,092,113	100.0%	\$17,742,521,656	100.0%	\$1,024,429,543	6.1%

*In 2022-23 dispensing of COVID-19 therapies MOLNUPIRAVIR and NIRMATRELVIR (&) RITONAVIR through Doctors' Bag cost the government over \$60m, in 2023-24 this cost over \$110m

Table 2(c): RPBS and PBS Subsidised Prescriptions for DVA patients, 2022-23 and 2023-24

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2022-23		2023-24		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	4,096,074	57.7%	4,017,587	57.3%	-78,487	-1.9%
Repatriation Safety Net	3,001,688	42.3%	2,999,402	42.7%	-2,286	-0.1%
Total Repatriation	7,097,762	100.0%	7,016,989	100%	-80,773	-1.1%

Table 2(d): RPBS and PBS Government Cost for DVA patients, 2022-23 and 2023-24

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2022-23		2023-24		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$241,112,398	65.6%	\$254,615,836	66.1%	\$13,503,438	5.6%
Repatriation Safety Net	\$126,690,433	34.4%	\$130,773,554	33.9%	\$4,083,122	3.2%
Total Repatriation	\$367,802,831	100.0%	\$385,389,391	100.0%	\$17,586,559	4.8%

The figures in tables 2(c) and 2(d) will be different than figures currently published in the DVA Annual Report, as expenditure changes due to allowable pharmacy claim adjustments, and processing of historical or delayed claiming by providers.

PBS Expenditure and Prescriptions 2023-24

Table 3(a): PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2023-24
Section 85 only, including Doctors' Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
2023-24	Concessional Non-Safety Net	124,213,565	\$5,204,902,852	\$902,290,470	\$6,107,193,321	\$49.17
	Concessional Safety Net	72,559,557	\$2,942,450,137	\$0	\$2,942,450,137	\$40.55
	Total Concessional	196,773,122	\$8,147,352,988	\$902,290,470	\$9,049,643,458	\$45.99
	General Non-Safety Net	23,008,698	\$3,921,177,643	\$655,931,365	\$4,577,109,008	\$198.93
	General Safety Net	2,059,976	\$97,075,860	\$14,179,368	\$111,255,228	\$54.01
	Total General	25,068,674	\$4,018,253,502	\$670,110,733	\$4,688,364,236	\$187.02
	Total (excluding Doctors' Bag)	221,841,796	\$12,165,606,491	\$1,572,401,203	\$13,738,007,694	\$61.93
	Doctors' Bag	422,617	\$131,296,722	\$0	\$131,296,722	\$310.68
	Total (including Doctors' Bag)	222,264,413	\$12,296,903,212	\$1,572,401,203	\$13,869,304,415	\$62.40

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.
 ** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.
 *** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 3(b): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2023-24
Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
2023-24	Concessional Non-Safety Net	126,069,354	\$7,564,422,947	\$912,941,797	\$8,477,364,744	\$67.24
	Concessional Safety Net	72,885,129	\$3,247,695,209	\$0	\$3,247,695,209	\$44.56
	Total Concessional	198,954,483	\$10,812,118,155	\$912,941,797	\$11,725,059,952	\$58.93
	General Non-Safety Net	25,056,303	\$6,686,174,489	\$703,982,641	\$7,390,157,131	\$294.94
	General Safety Net	2,075,206	\$112,932,290	\$14,276,000	\$127,208,291	\$61.30
	Total General	27,131,509	\$6,799,106,780	\$718,258,642	\$7,517,365,421	\$277.07
	Total (excluding Doctors' Bag)	226,085,992	\$17,611,224,935	\$1,631,200,439	\$19,242,425,374	\$85.11
	Doctors' Bag	422,617	\$131,296,722	\$0	\$131,296,722	\$310.68
	Total (including Doctors' Bag)	226,508,609	\$17,742,521,656	\$1,631,200,439	\$19,373,722,095	\$85.53

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.
 ** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.
 *** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Table 3(c): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2022-23 and 2023-24
Section 85 and Section 100, excluding Doctors' Bag and including under co-payment prescriptions

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)*	Total Cost**	Ave. Price***
2022-23	Jul	18,141,652	9,104,578	27,246,230	\$1,373,074,491	\$125,287,987	\$1,498,362,479	\$82.59
	Aug	19,332,255	9,370,367	28,702,622	\$1,445,394,149	\$121,698,362	\$1,567,092,512	\$81.06
	Sep	18,598,244	8,830,870	27,429,114	\$1,359,891,125	\$108,519,787	\$1,468,410,913	\$78.95
	Oct	18,833,921	8,797,566	27,631,487	\$1,338,429,522	\$103,347,107	\$1,441,776,629	\$76.55
	Nov	19,681,174	8,681,618	28,362,792	\$1,534,973,877	\$102,935,731	\$1,637,909,608	\$83.22
	Dec	21,874,775	8,611,815	30,486,590	\$1,632,608,664	\$100,315,796	\$1,732,924,461	\$79.22
2023-24	Jan	15,868,078	8,231,907	24,099,985	\$1,247,611,538	\$148,525,817	\$1,396,137,355	\$87.98
	Feb	16,269,696	8,019,194	24,288,890	\$1,206,403,308	\$150,972,329	\$1,357,375,637	\$83.43
	Mar	18,837,961	9,076,970	27,914,931	\$1,431,395,630	\$170,952,333	\$1,602,347,963	\$85.06
	Apr	17,037,101	8,457,449	25,494,550	\$1,209,794,273	\$145,542,798	\$1,355,337,072	\$79.55
	May	19,581,285	9,388,924	28,970,209	\$1,479,702,638	\$153,379,403	\$1,633,082,041	\$83.40
	Jun	18,709,242	9,045,132	27,754,374	\$1,378,623,381	\$132,945,404	\$1,511,568,785	\$80.79
Total		222,765,384	105,616,390	328,381,774	\$16,637,902,597	\$1,564,422,856	\$18,202,325,453	\$81.71
2022-23	Jul	18,895,028	9,124,204	28,019,232	\$1,368,545,596	\$124,063,952	\$1,492,609,548	\$78.99
	Aug	20,009,820	9,386,395	29,396,215	\$1,494,405,498	\$120,813,823	\$1,615,219,321	\$80.72
	Sep	18,946,504	8,786,481	27,732,985	\$1,406,386,033	\$107,597,035	\$1,513,983,068	\$79.91
	Oct	19,791,889	8,781,725	28,573,614	\$1,498,118,089	\$106,566,281	\$1,604,684,370	\$81.08
	Nov	20,117,179	8,539,409	28,656,588	\$1,587,876,769	\$102,495,583	\$1,690,372,352	\$84.03
	Dec	21,570,633	8,428,395	29,999,028	\$1,604,579,715	\$98,432,640	\$1,703,012,355	\$78.95
2023-24	Jan	16,577,417	8,667,505	25,244,922	\$1,389,594,235	\$166,314,523	\$1,555,908,757	\$93.86
	Feb	17,069,186	8,498,491	25,567,677	\$1,380,356,339	\$169,298,774	\$1,549,655,113	\$90.79
	Mar	17,651,298	8,822,622	26,473,920	\$1,397,517,295	\$171,375,605	\$1,568,892,900	\$88.88
	Apr	18,140,741	8,878,635	27,019,376	\$1,432,484,307	\$164,726,530	\$1,597,210,837	\$88.05
	May	19,511,377	9,349,717	28,861,094	\$1,598,446,513	\$162,656,744	\$1,761,103,257	\$90.26
	Jun	17,804,920	8,748,140	26,553,060	\$1,452,914,546	\$136,858,950	\$1,589,773,495	\$89.29
Total		226,085,992	106,011,719	332,097,711	\$17,611,224,935	\$1,631,200,439	\$19,242,425,374	\$85.11

* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.
 ** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.
 *** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

PBS Expenditure and Prescriptions 2023-24

Table 4: PBS Subsidised Prescriptions by Pharmacy State, 2023-24

Section 85 and Section 100, excluding Doctors' Bag and excluding under co-payment prescriptions

PBS S85 subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	39,449,690	30,702,976	26,357,325	10,439,582	11,781,749	3,581,069	516,369	1,384,805	124,213,565
Concessional Safety Net	23,889,267	17,868,579	15,027,806	6,166,458	6,502,308	2,184,171	162,956	758,012	72,559,557
General Non-Safety Net	7,324,770	5,555,040	4,781,232	1,457,422	2,646,568	525,017	204,034	514,615	23,008,698
General Safety Net	707,083	492,043	378,218	127,491	241,469	45,936	7,259	60,477	2,059,976
Total	71,370,810	54,618,638	46,544,581	18,190,953	21,172,094	6,336,193	890,618	2,717,909	221,841,796
PBS (S85 + S100) subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	40,036,060	31,177,636	26,732,999	10,585,832	11,953,130	3,625,550	529,660	1,428,487	126,069,354
Concessional Safety Net	23,983,908	17,961,550	15,093,722	6,193,137	6,533,036	2,192,450	164,546	762,780	72,885,129
General Non-Safety Net	8,001,694	6,074,100	5,151,915	1,582,443	2,854,839	556,511	220,897	613,904	25,056,303
General Safety Net	710,599	497,407	381,764	128,192	242,941	46,209	7,289	60,805	2,075,206
Total	72,732,261	55,710,693	47,360,400	18,489,604	21,583,946	6,420,720	922,392	2,865,976	226,085,992
Government Cost (S85 only)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$1,699,425,845	\$1,271,033,852	\$1,070,038,215	\$435,937,340	\$499,963,281	\$150,099,352	\$20,119,408	\$58,285,560	\$5,204,902,852
Concessional Safety Net	\$958,062,181	\$731,984,561	\$594,239,208	\$252,445,121	\$273,671,456	\$92,284,984	\$5,621,448	\$34,141,178	\$2,942,450,137
General Non-Safety Net	\$1,269,406,439	\$1,046,751,466	\$714,231,184	\$264,619,003	\$425,226,336	\$92,743,200	\$25,482,390	\$82,717,626	\$3,921,177,643
General Safety Net	\$32,810,953	\$23,732,031	\$17,241,722	\$6,004,858	\$11,690,533	\$2,113,514	\$302,764	\$3,179,486	\$97,075,860
Total	\$3,959,705,418	\$3,073,501,909	\$2,395,750,328	\$959,006,322	\$1,210,551,605	\$337,241,050	\$51,526,010	\$178,323,849	\$12,165,606,491
Government Cost (S85 + S100)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$2,426,539,628	\$1,809,609,776	\$1,638,234,890	\$626,389,574	\$725,037,520	\$218,393,124	\$30,619,261	\$89,599,174	\$7,564,422,947
Concessional Safety Net	\$1,034,720,523	\$809,887,109	\$669,257,016	\$284,076,816	\$302,435,534	\$103,969,871	\$6,406,447	\$36,941,892	\$3,247,695,209
General Non-Safety Net	\$2,182,834,908	\$1,731,828,744	\$1,260,172,702	\$426,599,648	\$743,115,360	\$137,744,051	\$45,187,029	\$158,692,048	\$6,686,174,489
General Safety Net	\$36,461,615	\$28,773,355	\$20,710,884	\$7,135,449	\$13,642,406	\$2,468,064	\$326,564	\$3,413,953	\$112,932,290
Total	\$5,680,556,674	\$4,380,098,985	\$3,588,375,493	\$1,344,201,485	\$1,784,230,819	\$462,575,110	\$82,539,301	\$288,647,068	\$17,611,224,935
Total Cost (S85 + S100)*	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$2,714,295,458	\$2,041,683,333	\$1,828,499,874	\$703,679,473	\$811,151,895	\$244,358,922	\$33,573,435	\$100,122,353	\$8,477,364,744
Concessional Safety Net	\$1,034,720,523	\$809,887,109	\$669,257,016	\$284,076,816	\$302,435,534	\$103,969,871	\$6,406,447	\$36,941,892	\$3,247,695,209
General Non-Safety Net	\$2,403,803,406	\$1,911,752,419	\$1,399,327,829	\$471,649,700	\$824,201,795	\$152,617,871	\$50,017,330	\$176,786,780	\$7,390,157,131
General Safety Net	\$41,304,408	\$32,333,252	\$23,247,387	\$8,025,117	\$15,325,679	\$2,771,875	\$357,751	\$3,842,821	\$127,208,291
Total	\$6,194,123,796	\$4,795,656,113	\$3,920,332,106	\$1,467,431,106	\$1,953,114,903	\$503,718,540	\$90,354,964	\$317,693,847	\$19,242,425,374
Population Percentage	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Population**	8,428,215	6,903,901	5,527,248	1,866,388	2,928,484	574,717	253,815	470,018	26,957,776
PBS S85 Subsidised Scripts per Capita	8.47	7.91	8.42	9.75	7.23	11.02	3.51	5.78	8.23
PBS (S85 + S100) Subsidised Scripts per Capita	8.63	8.07	8.57	9.91	7.37	11.17	3.63	6.10	8.39
PBS S85 Govt Cost per Capita	\$469.82	\$445.18	\$433.44	\$513.83	\$413.37	\$586.79	\$203.01	\$379.40	\$451.28
PBS (S85 + S100) Govt Cost per Capita	\$673.99	\$634.44	\$649.22	\$720.22	\$609.27	\$804.87	\$325.19	\$614.12	\$653.29
Population Percentage	31.26%	25.61%	20.50%	6.92%	10.86%	2.13%	0.94%	1.74%	100.00%
PBS (S85 + S100) Subsidised Scripts Percentage	32.17%	24.64%	20.95%	8.18%	9.55%	2.84%	0.41%	1.27%	100.00%
PBS (S85 + S100) Govt Cost Percentage	32.26%	24.87%	20.38%	7.63%	10.13%	2.63%	0.47%	1.64%	100.00%
Total Cost Percentage	32.19%	24.92%	20.37%	7.63%	10.15%	2.62%	0.47%	1.65%	100.00%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 + S100 prescriptions).

**Population 31 December 2023, Source: ABS Publication 3101.04

PBS Expenditure and Prescriptions 2023-24

Table 5(a): Top 50 PBS Drugs (by Active Ingredient) by Highest Government Cost, 2023-24
 Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (& IVACAFTOR)	26,587	\$568,268,710	\$367,331	\$568,636,041	\$21,387.75
2	PEMBROLIZUMAB	66,560	\$566,997,047	\$299,405	\$567,296,452	\$8,523.08
3	NIVOLUMAB	60,573	\$437,624,544	\$233,625	\$437,858,169	\$7,228.60
4	USTEKINUMAB	60,131	\$435,514,789	\$1,404,238	\$436,919,027	\$7,266.12
5	MOLNUPIRAVIR	365,625	\$424,465,667	\$4,292,175	\$428,757,842	\$1,172.67
6	AFLIBERCEPT	423,776	\$414,352,955	\$5,624,971	\$419,977,926	\$991.04
7	DUPILUMAB	213,318	\$366,173,611	\$4,994,865	\$371,168,476	\$1,739.98
8	APIXABAN	4,043,526	\$336,135,202	\$40,193,026	\$376,328,229	\$93.07
9	NIRMATRELVIR (&) RITONAVIR	267,746	\$324,216,657	\$3,874,648	\$328,091,306	\$1,225.38
10	DENOSUMAB	1,154,845	\$291,440,721	\$11,559,074	\$302,999,794	\$262.37
11	SEMAGLUTIDE	2,397,521	\$284,633,101	\$36,471,199	\$321,104,299	\$133.93
12	ADALIMUMAB	355,511	\$246,413,570	\$7,753,550	\$254,167,121	\$714.93
13	OCRELIZUMAB	13,721	\$225,270,661	\$357,252	\$225,627,913	\$16,443.98
14	UPADACITINIB	150,669	\$211,184,905	\$3,162,517	\$214,347,422	\$1,422.64
15	DARATUMUMAB	25,597	\$182,995,797	\$352,877	\$183,348,674	\$7,162.90
16	OSIMERTINIB	20,842	\$163,467,414	\$335,331	\$163,802,746	\$7,859.26
17	GLECAPREVIR + PIBRENTASVIR	9,167	\$160,941,379	\$207,488	\$161,148,866	\$17,579.24
18	ENZALUTAMIDE	45,672	\$157,994,896	\$504,502	\$158,499,398	\$3,470.38
19	IPILIMUMAB	7,599	\$153,386,733	\$58,873	\$153,445,606	\$20,192.87
20	VEDOLIZUMAB	63,372	\$153,355,936	\$1,604,028	\$154,959,963	\$2,445.24
21	GUSELKUMAB	39,868	\$148,534,932	\$918,211	\$149,453,143	\$3,748.70
22	SACUBITRIL + VALSARTAN	765,411	\$144,704,947	\$8,499,974	\$153,204,921	\$200.16
23	FERRIC CARBOXYMALTOSE	536,032	\$144,187,906	\$11,687,208	\$155,875,114	\$290.79
24	ATEZOLIZUMAB	19,009	\$137,113,654	\$92,972	\$137,206,626	\$7,217.98
25	RIVAROXABAN	2,595,221	\$137,016,631	\$29,423,467	\$166,440,097	\$64.13
26	SOFOSBUVIR + VELPATASVIR	10,953	\$131,122,395	\$197,754	\$131,320,150	\$11,989.42
27	FARICIMAB	116,842	\$124,764,100	\$1,555,925	\$126,320,024	\$1,081.12
28	LISDEXAMFETAMINE	1,542,855	\$119,683,727	\$36,433,831	\$156,117,558	\$101.19
29	ROSUVASTATIN	9,806,213	\$117,660,751	\$48,640,480	\$166,301,231	\$16.96
30	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	67,547	\$114,824,005	\$1,563,840	\$116,387,844	\$1,723.06
31	DURVALUMAB	10,752	\$113,444,508	\$56,484	\$113,500,992	\$10,556.27
32	CEMIPLIMAB	14,419	\$107,712,803	\$42,711	\$107,755,514	\$7,473.16
33	SECUKINUMAB	75,495	\$103,900,649	\$1,644,208	\$105,544,857	\$1,398.04
34	RISANKIZUMAB	18,110	\$97,369,950	\$438,882	\$97,808,832	\$5,400.82
35	RUXOLITINIB	21,305	\$97,369,241	\$290,079	\$97,659,321	\$4,583.87
36	RIBOCICLIB	21,124	\$94,929,668	\$351,727	\$95,281,395	\$4,510.58
37	BUPRENORPHINE	1,379,299	\$94,585,564	\$10,226,497	\$104,812,060	\$75.99
38	RANIBIZUMAB	108,632	\$92,576,340	\$1,318,079	\$93,894,420	\$864.33
39	ATORVASTATIN	7,783,994	\$91,996,207	\$36,876,764	\$128,872,970	\$16.56
40	ETANERCEPT	107,149	\$89,111,271	\$1,873,664	\$90,984,936	\$849.14
41	INFLIXIMAB	98,550	\$88,111,661	\$2,537,906	\$90,649,568	\$919.83
42	GOLIMUMAB	76,372	\$87,005,529	\$1,630,640	\$88,636,168	\$1,160.58
43	EMPAGLIFLOZIN	1,751,194	\$85,709,218	\$21,561,843	\$107,271,061	\$61.26
44	LENALIDOMIDE	47,638	\$84,505,510	\$774,442	\$85,279,952	\$1,790.17
45	PALBOCICLIB	19,853	\$83,701,486	\$269,734	\$83,971,220	\$4,229.65
46	PANTOPRAZOLE	7,206,109	\$83,593,296	\$33,295,466	\$116,888,762	\$16.22
47	IBRUTINIB	9,692	\$81,936,652	\$104,354	\$82,041,007	\$8,464.82
48	DARBEPOETIN ALFA	84,772	\$78,579,890	\$1,020,280	\$79,600,171	\$938.99
49	ZANUBRUTINIB	9,625	\$76,824,608	\$118,419	\$76,943,028	\$7,994.08
50	CLADRIBINE	4,725	\$76,307,661	\$99,971	\$76,407,633	\$16,170.93

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.
 ** Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.
 *** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

PBS Expenditure and Prescriptions 2023-24

Table 5(b): Top 50 PBS Drugs (by Active Ingredient) by Highest Subsidised Prescriptions, 2023-24
Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	ROSUVASTATIN	9,806,213	\$117,660,751	\$48,640,480	\$166,301,231	\$16.96
2	ATORVASTATIN	7,783,994	\$91,996,207	\$36,876,764	\$128,872,970	\$16.56
3	PANTOPRAZOLE	7,206,109	\$83,593,296	\$33,295,466	\$116,888,762	\$16.22
4	ESOMEPRAZOLE	5,508,666	\$71,930,326	\$25,543,782	\$97,474,107	\$17.69
5	APIXABAN	4,043,526	\$336,135,202	\$40,193,026	\$376,328,229	\$93.07
6	PERINDOPRIL	4,020,943	\$47,466,070	\$20,157,142	\$67,623,212	\$16.82
7	METFORMIN	3,691,000	\$47,760,730	\$15,611,899	\$63,372,630	\$17.17
8	AMLODIPINE	3,200,925	\$35,629,865	\$15,154,150	\$50,784,015	\$15.87
9	PREGABALIN	2,987,444	\$48,902,386	\$11,781,854	\$60,684,240	\$20.31
10	SALBUTAMOL	2,709,901	\$53,309,674	\$10,985,981	\$64,295,654	\$23.73
11	RIVAROXABAN	2,595,221	\$137,016,631	\$29,423,467	\$166,440,097	\$64.13
12	SERTRALINE	2,515,979	\$28,467,851	\$13,461,119	\$41,928,970	\$16.67
13	TELMISARTAN	2,506,878	\$28,757,590	\$12,917,100	\$41,674,690	\$16.62
14	IRBESARTAN	2,495,808	\$28,597,727	\$12,122,280	\$40,720,007	\$16.32
15	ESCITALOPRAM	2,481,531	\$27,404,735	\$13,472,939	\$40,877,673	\$16.47
16	CANDESARTAN	2,480,054	\$28,885,063	\$12,525,286	\$41,410,349	\$16.70
17	MIRTAZAPINE	2,429,311	\$30,534,564	\$11,083,623	\$41,618,187	\$17.13
18	SEMAGLUTIDE	2,397,521	\$284,633,101	\$36,471,199	\$321,104,299	\$133.93
19	CEFALEXIN	2,328,416	\$26,113,577	\$12,530,104	\$38,643,681	\$16.60
20	BUDESONIDE + FORMOTEROL	2,146,390	\$63,479,919	\$35,943,587	\$99,423,506	\$46.32
21	RAMIPRIL	1,961,521	\$22,683,683	\$9,275,290	\$31,958,973	\$16.29
22	OXYCODONE	1,940,460	\$48,005,153	\$10,481,360	\$58,486,512	\$30.14
23	DUTASTERIDE + TAMSULOSIN	1,862,651	\$46,414,706	\$11,190,049	\$57,604,755	\$30.93
24	METOPROLOL TARTRATE	1,844,845	\$21,241,185	\$7,782,593	\$29,023,778	\$15.73
25	VENLAFAXINE	1,834,146	\$23,883,920	\$9,569,062	\$33,452,982	\$18.24
26	BISOPROLOL	1,815,707	\$25,596,572	\$7,789,281	\$33,385,854	\$18.39
27	PARACETAMOL	1,811,452	\$29,112,845	\$6,165,809	\$35,278,654	\$19.48
28	ATENOLOL	1,811,397	\$21,415,735	\$8,305,569	\$29,721,304	\$16.41
29	AMOXICILLIN	1,808,003	\$20,052,580	\$10,547,256	\$30,599,836	\$16.92
30	AMITRIPTYLINE	1,779,319	\$21,840,336	\$7,921,011	\$29,761,347	\$16.73
31	EMPAGLIFLOZIN	1,751,194	\$85,709,218	\$21,561,843	\$107,271,061	\$61.26
32	PARACETAMOL + CODEINE	1,750,863	\$40,797,568	\$9,803,056	\$50,600,624	\$28.90
33	CLOPIDOGREL	1,748,096	\$22,984,778	\$7,083,887	\$30,068,665	\$17.20
34	FLUTICASONE PROPIONATE + SALMETEROL	1,726,758	\$59,313,230	\$26,554,087	\$85,867,316	\$49.73
35	LERCANIDIPINE	1,652,652	\$19,941,036	\$7,294,704	\$27,235,740	\$16.48
36	RABEPRAZOLE	1,641,919	\$19,689,337	\$7,613,130	\$27,302,467	\$16.63
37	PERINDOPRIL + AMLODIPINE	1,634,437	\$21,170,464	\$8,904,971	\$30,075,436	\$18.40
38	LISDEXAMFETAMINE	1,542,855	\$119,683,727	\$36,433,831	\$156,117,558	\$101.19
39	DAPAGLIFLOZIN	1,525,456	\$69,331,927	\$18,237,581	\$87,569,508	\$57.41
40	FUROSEMIDE	1,439,818	\$18,492,457	\$5,394,088	\$23,886,544	\$16.59
41	METHYLPHENIDATE	1,438,540	\$49,526,996	\$26,251,905	\$75,778,900	\$52.68
42	SITAGLIPTIN + METFORMIN	1,433,197	\$45,530,110	\$18,971,034	\$64,501,144	\$45.01
43	AMOXICILLIN + CLAVULANIC ACID	1,391,711	\$16,775,276	\$7,626,743	\$24,402,019	\$17.53
44	BUPRENORPHINE	1,379,299	\$94,585,564	\$10,226,497	\$104,812,060	\$75.99
45	DULOXETINE	1,344,840	\$19,181,254	\$6,475,503	\$25,656,757	\$19.08
46	SIMVASTATIN	1,333,973	\$15,227,313	\$6,139,352	\$21,366,665	\$16.02
47	OXYCODONE + NALOXONE	1,331,954	\$52,490,683	\$10,366,212	\$62,856,894	\$47.19
48	PREDNISOLONE	1,317,197	\$15,333,527	\$5,995,043	\$21,328,570	\$16.19
49	GLICLAZIDE	1,305,212	\$18,371,259	\$4,891,339	\$23,262,598	\$17.82
50	MELOXICAM	1,302,503	\$15,596,215	\$6,426,875	\$22,023,090	\$16.91

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

PBS Expenditure and Prescriptions 2023-24

Table 5(c): Top 25 PBS Antineoplastic Drugs (by Active Ingredient) by Highest Government Cost, 2023-24
Section 85 and Section 100, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	PEMBROLIZUMAB	66,560	\$566,997,047	\$299,405	\$567,296,452	\$8,523.08
2	NIVOLUMAB	60,573	\$437,624,544	\$233,625	\$437,858,169	\$7,228.60
3	OSIMERTINIB	20,842	\$163,467,414	\$335,331	\$163,802,746	\$7,859.26
4	ENZALUTAMIDE	45,672	\$157,994,896	\$504,502	\$158,499,398	\$3,470.38
5	IPILIMUMAB	7,599	\$153,386,733	\$58,873	\$153,445,606	\$20,192.87
6	DARATUMUMAB^^	21,294	\$152,408,683	\$280,370	\$152,689,053	\$7,170.52
7	ATEZOLIZUMAB	19,009	\$137,113,654	\$92,972	\$137,206,626	\$7,217.98
8	DURVALUMAB	10,752	\$113,444,508	\$56,484	\$113,500,992	\$10,556.27
9	CEMIPLIMAB	14,419	\$107,712,803	\$42,711	\$107,755,514	\$7,473.16
10	RIBOCICLIB	21,124	\$94,929,668	\$351,727	\$95,281,395	\$4,510.58
11	LENALIDOMIDE	47,638	\$84,505,510	\$774,442	\$85,279,952	\$1,790.17
12	PALBOCICLIB	19,853	\$83,701,486	\$269,734	\$83,971,220	\$4,229.65
13	IBRUTINIB	9,692	\$81,936,652	\$104,354	\$82,041,007	\$8,464.82
14	RUXOLITINIB	16,972	\$80,014,833	\$217,781	\$80,232,614	\$4,727.35
15	ZANUBRUTINIB	9,625	\$76,824,608	\$118,419	\$76,943,028	\$7,994.08
16	VENETOCLAX	12,115	\$74,129,050	\$167,242	\$74,296,292	\$6,132.59
17	PERTUZUMAB	21,997	\$69,248,719	\$128,293	\$69,377,013	\$3,153.93
18	ACALABRUTINIB	8,299	\$64,954,631	\$99,295	\$65,053,926	\$7,838.77
19	BEVACIZUMAB	68,634	\$63,348,820	\$370,806	\$63,719,626	\$928.40
20	DAROLUTAMIDE	16,824	\$58,919,406	\$229,036	\$59,148,442	\$3,515.72
21	AVELUMAB	9,550	\$56,602,215	\$27,092	\$56,629,307	\$5,929.77
22	OBINUTUZUMAB	11,748	\$55,181,111	\$43,174	\$55,224,285	\$4,700.74
23	ABIRATERONE	15,666	\$53,117,463	\$151,507	\$53,268,970	\$3,400.29
24	GOSERELIN^	133,081	\$52,975,159	\$2,592,205	\$55,567,364	\$417.55
25	ABEMACICLIB	11,002	\$46,317,975	\$185,883	\$46,503,858	\$4,226.85

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.
 ** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.
 *** Average Price is Total Cost divided by PBS Subsidised Prescriptions.
 ^ Some of the usage may be for treating other conditions.
 ^^ Excludes PBS items that are not for cancer treatment.

Table 5(d): Top 25 PBS Biological Products and Medicines by Highest Government Cost, 2023-24
Section 85 and Section 100, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	PEMBROLIZUMAB	66,560	\$566,997,047	\$299,405	\$567,296,452	\$8,523.08
2	NIVOLUMAB	60,573	\$437,624,544	\$233,625	\$437,858,169	\$7,228.60
3	USTEKINUMAB	60,131	\$435,514,789	\$1,404,238	\$436,919,027	\$7,266.12
4	AFLIBERCEPT	423,776	\$414,352,955	\$5,624,971	\$419,977,926	\$991.04
5	DUPILUMAB	213,318	\$366,173,611	\$4,994,865	\$371,168,476	\$1,739.98
6	DENOSUMAB	1,154,845	\$291,440,721	\$11,559,074	\$302,999,794	\$262.37
7	SEMAGLUTIDE	2,397,521	\$284,633,101	\$36,471,199	\$321,104,299	\$133.93
8	ADALIMUMAB	355,511	\$246,413,570	\$7,753,550	\$254,167,121	\$714.93
9	OCRELIZUMAB	13,721	\$225,270,661	\$357,252	\$225,627,913	\$16,443.98
10	DARATUMUMAB	25,597	\$182,995,797	\$352,877	\$183,348,674	\$7,162.90
11	IPILIMUMAB	7,599	\$153,386,733	\$58,873	\$153,445,606	\$20,192.87
12	VEDOLIZUMAB	63,372	\$153,355,936	\$1,604,028	\$154,959,963	\$2,445.24
13	GUSELKUMAB	39,868	\$148,534,932	\$918,211	\$149,453,143	\$3,748.70
14	ATEZOLIZUMAB	19,009	\$137,113,654	\$92,972	\$137,206,626	\$7,217.98
15	FARICIMAB	116,842	\$124,764,100	\$1,555,925	\$126,320,024	\$1,081.12
16	DURVALUMAB	10,752	\$113,444,508	\$56,484	\$113,500,992	\$10,556.27
17	CEMIPLIMAB	14,419	\$107,712,803	\$42,711	\$107,755,514	\$7,473.16
18	SECUKINUMAB	75,495	\$103,900,649	\$1,644,208	\$105,544,857	\$1,398.04
19	RISANKIZUMAB	18,110	\$97,369,950	\$438,882	\$97,808,832	\$5,400.82
20	RANIBIZUMAB	108,632	\$92,576,340	\$1,318,079	\$93,894,420	\$864.33
21	ETANERCEPT	107,149	\$89,111,271	\$1,873,664	\$90,984,936	\$849.14
22	INFLIXIMAB	98,550	\$88,111,661	\$2,537,906	\$90,649,568	\$919.83
23	GOLIMUMAB	76,372	\$87,005,529	\$1,630,640	\$88,636,168	\$1,160.58
24	DARBEPOETIN ALFA	84,772	\$78,579,890	\$1,020,280	\$79,600,171	\$938.99
25	RAVULIZUMAB	1,204	\$73,305,948	\$30,827	\$73,336,774	\$60,910.94

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.
 ** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.
 *** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

PBS Expenditure and Prescriptions 2023-24

Table 5(e): Top 50 PBS Brands, excluding Efficient Funding of Chemotherapy (EFC) by Highest Government Cost, 2023-24
Section 85 and Section 100, excluding under co-payment prescriptions

Rank	Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	Trikafta®	ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR	26,587	\$568,268,710	\$367,331	\$568,636,041	\$21,387.75
2	Stelara®	USTEKINUMAB	60,130	\$435,506,941	\$1,404,206	\$436,911,147	\$7,266.11
3	Lagevrio®	MOLNUPIRAVIR	365,604	\$424,442,852	\$4,291,843	\$428,734,695	\$1,172.68
4	Eylea®	AFLIBERCEPT	423,774	\$414,351,213	\$5,624,932	\$419,976,146	\$991.04
5	Dupilixent®	DUPILUMAB	213,314	\$366,166,812	\$4,994,826	\$371,161,638	\$1,739.98
6	Eliquis®	APIXABAN	4,043,501	\$336,133,258	\$40,192,744	\$376,326,002	\$93.07
7	Paxlovid®	NIRMATRELVIR (&) RITONAVIR	267,744	\$324,214,428	\$3,874,648	\$328,089,076	\$1,225.38
8	Ozempic®	SEMAGLUTIDE	2,397,495	\$284,629,897	\$36,470,923	\$321,100,820	\$133.93
9	Prolia®	DENOSUMAB	1,092,474	\$263,937,593	\$10,715,353	\$274,652,946	\$251.40
10	Ocrevus®	OCRELIZUMAB	13,721	\$225,270,661	\$357,252	\$225,627,913	\$16,443.98
11	Rinvoq®	UPADACITINIB	150,669	\$211,184,905	\$3,162,517	\$214,347,422	\$1,422.64
12	Humira®	ADALIMUMAB	269,878	\$179,876,215	\$5,967,382	\$185,843,597	\$688.62
13	Darzalex SC®	DARATUMUMAB	23,791	\$169,234,028	\$348,396	\$169,582,424	\$7,128.01
14	Tagrisso®	OSIMERTINIB	20,842	\$163,467,414	\$335,331	\$163,802,746	\$7,859.26
15	Maviret®	GLECAPREVIR + PIBRENTASVIR	9,166	\$160,923,490	\$207,480	\$161,130,971	\$17,579.20
16	Xtandi®	ENZALUTAMIDE	45,672	\$157,994,896	\$504,502	\$158,499,398	\$3,470.38
17	Entyvio®	VEDOLIZUMAB	63,372	\$153,355,936	\$1,604,028	\$154,959,963	\$2,445.24
18	Tremfya®	GUSELKUMAB	39,868	\$148,534,932	\$918,211	\$149,453,143	\$3,748.70
19	Entresto®	SACUBITRIL + VALSARTAN	765,403	\$144,303,289	\$8,499,912	\$153,203,201	\$200.16
20	Ferinject®	FERRIC CARBOXYMALTOSE	536,029	\$144,187,075	\$11,687,140	\$155,874,215	\$290.79
21	Xarelto®	RIVAROXABAN	2,595,213	\$137,016,207	\$29,423,397	\$166,439,604	\$64.13
22	Epclusa®	SOFOSBUVIR + VELPATASVIR	10,953	\$131,122,395	\$197,754	\$131,320,150	\$11,989.42
23	Vabysmo®	FARICIMAB	116,842	\$124,764,100	\$1,555,925	\$126,320,024	\$1,081.12
24	Vyvanse®	LISDEXAMFETAMINE	1,542,845	\$119,682,950	\$36,433,608	\$156,116,558	\$101.19
25	Biktarvy®	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	67,547	\$114,824,005	\$1,563,840	\$116,387,844	\$1,723.06
26	Cosentyx®	SECUKINUMAB	75,495	\$103,900,649	\$1,644,208	\$105,544,857	\$1,398.04
27	Skyrizi®	RISANKIZUMAB	18,110	\$97,369,950	\$438,882	\$97,808,832	\$5,400.82
28	Jakavi®	RUXOLITINIB	21,305	\$97,369,241	\$290,079	\$97,659,321	\$4,583.87
29	Kisqali®	RIBOCICLIB	21,124	\$94,929,668	\$351,727	\$95,281,395	\$4,510.58
30	Lucentis®	RANIBIZUMAB	108,632	\$92,576,340	\$1,318,079	\$93,894,420	\$864.33
31	Simponi®	GOLIMUMAB	76,371	\$87,004,399	\$1,630,608	\$88,635,007	\$1,160.58
32	Jardiance®	EMPAGLIFLOZIN	1,751,184	\$85,708,731	\$21,561,720	\$107,270,451	\$61.26
33	Ibrance®	PALBOCICLIB	19,853	\$83,701,486	\$269,734	\$83,971,220	\$4,229.65
34	Imbruvica®	IBRUTINIB	9,692	\$81,936,652	\$104,354	\$82,041,007	\$8,464.82
35	Brukinsa®	ZANUBRUTINIB	9,624	\$76,816,684	\$118,412	\$76,935,096	\$7,994.09
36	Mavenclad®	CLADRIBINE	4,246	\$75,917,297	\$96,610	\$76,013,907	\$17,902.47
37	Venclexta®	VENETOCLAX	12,115	\$74,129,050	\$167,242	\$74,296,292	\$6,132.59
38	Ultomiris®	RAVULIZUMAB	1,204	\$73,305,948	\$30,827	\$73,336,774	\$60,910.94
39	Xolair®	OMALIZUMAB	70,549	\$72,222,154	\$1,524,334	\$73,746,488	\$1,045.32
40	Fasenra Pen®	BENRALIZUMAB	21,691	\$71,452,310	\$382,278	\$71,834,588	\$3,311.72
41	Lonquex®	LIPEGFILGRASTIM	62,413	\$69,876,495	\$1,354,512	\$71,231,007	\$1,141.28
42	Forxiga®	DAPAGLIFLOZIN	1,525,445	\$69,331,407	\$18,237,473	\$87,568,881	\$57.41
43	Ofev®	NINTEDANIB	26,348	\$68,935,761	\$300,557	\$69,236,318	\$2,627.76
44	Botox®	BOTULINUM TOXIN TYPE A	131,059	\$66,096,071	\$3,002,879	\$69,098,949	\$527.24
45	Crysvita®	BUROSUMAB	3,058	\$64,955,831	\$69,154	\$65,024,986	\$21,263.89
46	Taltz®	IXEKIZUMAB	20,004	\$64,669,910	\$445,971	\$65,115,881	\$3,255.14
47	Aranesp®	DARBEPOETIN ALFA	68,955	\$64,488,895	\$863,772	\$65,352,668	\$947.76
48	Kesimpta®	OFATUMUMAB	26,983	\$63,517,231	\$618,205	\$64,135,435	\$2,376.88
49	Nucala®	MEPOLIZUMAB	38,984	\$61,683,206	\$731,002	\$62,414,208	\$1,601.02
50	Ajovy®	FREMANEZUMAB	113,586	\$61,060,983	\$2,536,914	\$63,597,897	\$559.91

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Brand information is based on manufacturer code reported in the PBS Online Claims data. Brand information is excluded when the code is missing.

PBS Expenditure and Prescriptions 2023-24

Table 5(f): Top 50 PBS Brands (excluding EFC) by Highest Subsidised Prescriptions, 2023-24
Section 85 and Section 100, excluding under co-payment prescriptions

Rank	Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
1	Eliquis®	APIXABAN	4,043,501	\$336,133,258	\$40,192,744	\$376,326,002	\$93.07
2	Rosuvastatin Sandoz®	ROSUVASTATIN	2,625,330	\$30,754,473	\$13,813,095	\$44,567,569	\$16.98
3	Xarelto®	RIVAROXABAN	2,595,213	\$137,016,207	\$29,423,397	\$166,439,604	\$64.13
4	APX-Rosuvastatin®	ROSUVASTATIN	2,471,236	\$29,888,506	\$12,059,057	\$41,947,563	\$16.97
5	Ozempic®	SEMAGLUTIDE	2,397,495	\$284,629,897	\$36,470,923	\$321,100,820	\$133.93
6	APO-Atorvastatin®	ATORVASTATIN	2,277,744	\$27,402,492	\$10,369,090	\$37,771,582	\$16.58
7	Zempreon CFC-Free with dosecounter®	SALBUTAMOL	1,928,968	\$37,637,078	\$7,595,757	\$45,232,835	\$23.45
8	Atorvastatin SZ®	ATORVASTATIN	1,924,349	\$22,189,685	\$9,709,379	\$31,899,064	\$16.58
9	Pantoprazole Sandoz®	PANTOPRAZOLE	1,841,303	\$20,438,690	\$8,943,301	\$29,381,991	\$15.96
10	Lipitor®	ATORVASTATIN	1,809,648	\$21,031,152	\$8,790,992	\$29,822,144	\$16.48
11	Jardiance®	EMPAGLIFLOZIN	1,751,184	\$85,708,731	\$21,561,720	\$107,270,451	\$61.26
12	Pantoprazole APOTEX®	PANTOPRAZOLE	1,614,458	\$18,516,829	\$7,377,394	\$25,894,223	\$16.04
13	Vyvanse®	LISDEXAMFETAMINE	1,542,845	\$119,682,950	\$36,433,608	\$156,116,558	\$101.19
14	Forxiga®	DAPAGLIFLOZIN	1,525,445	\$69,331,407	\$18,237,473	\$87,568,881	\$57.41
15	APO-Esomeprazole®	ESOMEPRAZOLE	1,486,369	\$19,542,662	\$6,648,025	\$26,190,687	\$17.62
16	Crestor®	ROSUVASTATIN	1,484,843	\$17,342,163	\$7,717,771	\$25,059,934	\$16.88
17	Esopreze®	ESOMEPRAZOLE	1,476,656	\$18,737,073	\$7,254,514	\$25,991,588	\$17.60
18	Doubluts®	DUTASTERIDE + TAMSILOSIN	1,415,250	\$35,714,958	\$8,068,961	\$43,783,919	\$30.94
19	Somac®	PANTOPRAZOLE	1,294,399	\$15,834,643	\$6,393,444	\$22,228,087	\$17.17
20	Palexia SR®	TAPENTADOL	1,216,394	\$42,171,399	\$9,596,860	\$51,768,259	\$42.56
21	APO-Frusemide®	FUROSEMIDE	1,154,539	\$14,829,724	\$4,414,691	\$19,244,416	\$16.67
22	Cavstat®	ROSUVASTATIN	1,117,538	\$13,668,132	\$5,292,560	\$18,960,693	\$16.97
23	Prolia®	DENOSUMAB	1,092,474	\$263,937,593	\$10,715,353	\$274,652,946	\$251.40
24	Sozol®	PANTOPRAZOLE	1,063,930	\$12,409,470	\$4,661,847	\$17,071,317	\$16.05
25	APO-Cephalexin®	CEFALEXIN	1,044,930	\$11,732,236	\$5,390,630	\$17,122,866	\$16.39
26	Amlodipine Sandoz®	AMLODIPINE	930,685	\$10,031,010	\$4,719,733	\$14,750,743	\$15.85
27	Nexium®	ESOMEPRAZOLE	908,628	\$11,716,334	\$4,399,597	\$16,115,931	\$17.74
28	Atorvachol®	ATORVASTATIN	895,478	\$10,808,648	\$4,035,590	\$14,844,238	\$16.58
29	Xalatan®	LATANOPROST	876,212	\$11,292,504	\$4,023,761	\$15,316,265	\$17.48
30	Trajenta®	LINAGLIPTIN	872,750	\$44,014,811	\$7,750,829	\$51,765,640	\$59.31
31	APO-Telmisartan®	TELMISARTAN	865,403	\$10,124,093	\$4,234,266	\$14,358,359	\$16.59
32	Amlodipine APOTEX®	AMLODIPINE	859,005	\$9,607,090	\$4,027,830	\$13,634,920	\$15.87
33	Plidogrel®	CLOPIDOGREL	821,081	\$10,904,891	\$3,238,791	\$14,143,682	\$17.23
34	Escitalopram Sandoz®	ESCITALOPRAM	817,045	\$8,660,552	\$4,623,854	\$13,284,406	\$16.26
35	APX-Mirtazapine®	MIRTAZAPINE	808,581	\$10,188,222	\$3,615,619	\$13,803,841	\$17.07
36	Panafcortelone®	PREDNISOLONE	807,481	\$9,269,012	\$3,777,876	\$13,046,888	\$16.16
37	Sertraline Sandoz®	SERTRALINE	804,619	\$8,878,749	\$4,541,763	\$13,420,511	\$16.68
38	APO-Sertraline®	SERTRALINE	802,718	\$9,177,897	\$4,199,340	\$13,377,237	\$16.66
39	APO-Pregabalin®	PREGABALIN	797,466	\$13,048,677	\$3,065,087	\$16,113,763	\$20.21
40	APO-Candesartan®	CANDESARTAN	797,438	\$9,430,423	\$3,905,813	\$13,336,235	\$16.72
41	APX-Paracetamol/Codeine®	PARACETAMOL + CODEINE	788,169	\$18,290,635	\$4,265,352	\$22,555,987	\$28.62
42	Lyricea®	PREGABALIN	785,850	\$12,878,276	\$3,229,961	\$16,108,237	\$20.50
43	APO-Irbesartan®	IRBESARTAN	781,754	\$9,068,830	\$3,643,972	\$12,712,802	\$16.26
44	Osteomol 665 Paracetamol®	PARACETAMOL	781,655	\$13,244,985	\$2,584,470	\$15,829,455	\$20.25
45	Entresto®	SACUBITRIL + VALSARTAN	765,403	\$144,703,289	\$8,499,912	\$153,203,201	\$200.16
46	Lercanidipine APOTEX®	LERCANIDIPINE	757,027	\$9,243,541	\$3,202,219	\$12,445,760	\$16.44
47	Salpraz®	PANTOPRAZOLE	741,948	\$8,658,158	\$3,233,990	\$11,892,148	\$16.03
48	Janumet XR®	SITAGLIPTIN + METFORMIN	736,164	\$23,606,561	\$10,055,867	\$33,662,428	\$45.73
49	ARDIX GLICLAZIDE 60mg MR®	GLICLAZIDE	732,863	\$10,226,028	\$2,710,265	\$12,936,293	\$17.65
50	Spiriva Respimat®	TIOTROPIUM	720,820	\$25,202,615	\$6,494,575	\$31,697,190	\$43.97

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

PBS Expenditure and Prescriptions 2023-24

Table 5(g): Biosimilar Products and Medicines (excluding EFC) by Highest Government Cost, 2023-24
Section 85 and Section 100, excluding under co-payment prescriptions

Brand Name	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***
Brenzys®	ETANERCEPT	48,144	\$40,139,078	\$802,106	\$40,941,185	\$850.39
Inflectra®	INFLIXIMAB	25,487	\$26,052,440	\$671,631	\$26,724,071	\$1,048.54
Hyrimoz®	ADALIMUMAB	29,309	\$23,221,324	\$632,346	\$23,853,670	\$813.87
Remsima SC®	INFLIXIMAB	33,424	\$20,085,237	\$837,870	\$20,923,107	\$625.99
Amgevita®	ADALIMUMAB	23,851	\$18,829,149	\$488,879	\$19,318,028	\$809.95
Hadlima®	ADALIMUMAB	23,587	\$18,469,964	\$473,447	\$18,943,411	\$803.13
Renflexis®	INFLIXIMAB	13,770	\$13,952,426	\$347,578	\$14,300,004	\$1,038.49
Ovaleap®	FOLLITROPINALFA	6,821	\$8,907,466	\$202,178	\$9,109,644	\$1,335.53
Novicrit®	EPOETIN LAMBDA	6,342	\$6,777,375	\$69,533	\$6,846,908	\$1,079.61
Riximyo®	RITUXIMAB	11,811	\$4,543,288	\$258,078	\$4,801,365	\$406.52
Yuflyma®	ADALIMUMAB	5,179	\$3,319,039	\$115,562	\$3,434,601	\$663.18
Nivestim®	FILGRASTIM	9,996	\$2,085,770	\$192,042	\$2,277,812	\$227.87
Zarzio®	FILGRASTIM	9,601	\$1,887,286	\$162,488	\$2,049,774	\$213.50
Bemfola®	FOLLITROPINALFA	1,581	\$1,837,518	\$47,105	\$1,884,623	\$1,192.05
Ziextenzo®	PEGFILGRASTIM	16,075	\$1,706,779	\$341,472	\$2,048,251	\$127.42
Idacio®	ADALIMUMAB	1,968	\$1,545,259	\$40,433	\$1,585,693	\$805.74
Pelgraz®	PEGFILGRASTIM	15,829	\$1,521,523	\$387,442	\$1,908,965	\$120.60
Truxima®	RITUXIMAB	2,845	\$1,086,526	\$64,136	\$1,150,662	\$404.45
Terrosa®	TERIPARATIDE	6,346	\$1,050,606	\$72,878	\$1,123,483	\$177.04

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Brand information is based on manufacturer code reported in the PBS Online Claims data. Brand information is excluded when the code is missing. Biosimilars included in this report are based on Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme | Australian Government Department of Health and Aged Care. Excluding the reference brand.

PBS Expenditure and Prescriptions 2023-24

Table 6(a): Top 50 PBS Drugs (by Active Ingredient) by Highest Total Prescription Volume, 2023-24
 Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Government Cost
1	ROSUVASTATIN	9,806,213	6,935,779	16,741,992	\$117,660,751
2	ATORVASTATIN	7,783,994	3,878,821	11,662,815	\$91,996,207
3	PANTOPRAZOLE	7,206,109	3,418,669	10,624,778	\$83,593,296
4	ESOMEPRAZOLE	5,508,666	2,575,738	8,084,404	\$71,930,326
5	PERINDOPRIL	4,020,943	2,845,719	6,866,662	\$47,466,070
6	ESCITALOPRAM	2,481,531	3,860,883	6,342,414	\$27,404,735
7	METFORMIN	3,691,000	2,389,933	6,080,933	\$47,760,730
8	SERTRALINE	2,515,979	3,450,895	5,966,874	\$28,467,851
9	AMOXICILLIN	1,808,003	3,355,513	5,163,516	\$20,052,580
10	CEFALEXIN	2,328,416	2,737,695	5,066,111	\$26,113,577
11	AMLODIPINE	3,200,925	1,668,283	4,869,208	\$35,629,865
12	TELMISARTAN	2,506,878	1,917,730	4,424,608	\$28,757,590
13	CANDESARTAN	2,480,054	1,698,309	4,178,363	\$28,885,063
14	APIXABAN	4,043,526	364	4,043,890	\$336,135,202
15	PREGABALIN	2,987,444	896,512	3,883,956	\$48,902,386
16	IRBESARTAN	2,495,808	1,338,180	3,833,988	\$28,597,727
17	SALBUTAMOL	2,709,901	912,171	3,622,072	\$53,309,674
18	VENLAFAXINE	1,834,146	1,698,349	3,532,495	\$23,883,920
19	MIRTAZAPINE	2,429,311	1,023,742	3,453,053	\$30,534,564
20	AMOXICILLIN + CLAVULANIC ACID	1,391,711	1,933,437	3,325,148	\$16,775,276
21	RAMIPRIL	1,961,520	1,210,113	3,171,633	\$22,683,683
22	PERINDOPRIL + AMLODIPINE	1,634,437	1,512,478	3,146,915	\$21,170,464
23	OXYCODONE	1,940,461	1,082,808	3,023,269	\$48,005,153
24	PARACETAMOL + CODEINE	1,750,863	1,162,333	2,913,196	\$40,797,568
25	AMITRIPTYLINE	1,779,319	1,083,393	2,862,712	\$21,840,336
26	FLUOXETINE	1,204,544	1,530,651	2,735,195	\$17,540,684
27	DOXYCYCLINE	1,161,937	1,496,195	2,658,132	\$14,189,901
28	RIVAROXABAN	2,595,221	1,294	2,596,515	\$137,016,631
29	ATENOLOL	1,811,397	763,467	2,574,864	\$21,415,735
30	PREDNISOLONE	1,317,197	1,234,740	2,551,937	\$15,333,527
31	RABEPRAZOLE	1,641,919	882,595	2,524,514	\$19,689,337
32	METOPROLOL TARTRATE	1,844,845	657,394	2,502,239	\$21,241,185
33	BISOPROLOL	1,815,707	681,903	2,497,610	\$25,596,572
34	MELOXICAM	1,302,503	1,178,990	2,481,493	\$15,596,215
35	DESVENLAFAXINE	1,239,198	1,218,167	2,457,365	\$22,899,076
36	SEMAGLUTIDE	2,397,521	2	2,397,523	\$284,633,101
37	LERCANIDIPINE	1,652,652	610,019	2,262,671	\$19,941,036
38	DULOXETINE	1,344,840	916,527	2,261,367	\$19,181,254
39	CLOPIDOGREL	1,748,096	494,307	2,242,403	\$22,984,778
40	BUDESONIDE + FORMOTEROL	2,146,390	20,969	2,167,359	\$63,479,919
41	LEVOTHYROXINE	1,133,082	996,552	2,129,634	\$20,682,315
42	DUTASTERIDE + TAMSULOSIN	1,862,651	258,579	2,121,230	\$46,414,706
43	DIAZEPAM	1,300,029	820,284	2,120,313	\$13,277,043
44	PARACETAMOL	1,811,452	184,235	1,995,687	\$29,112,845
45	CELECOXIB	1,010,921	977,827	1,988,748	\$12,417,605
46	EZETIMIBE	1,280,368	603,270	1,883,638	\$19,617,319
47	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,204,878	598,982	1,803,860	\$14,357,656
48	GLICLAZIDE	1,305,212	496,189	1,801,401	\$18,371,259
49	EMPAGLIFLOZIN	1,751,194	99	1,751,293	\$85,709,218
50	METHYLPHENIDATE	1,438,540	293,660	1,732,200	\$49,526,996

PBS Expenditure and Prescriptions 2023-24


Table 6(b): Top 10 PBS Drugs (by Active Ingredient) per age group and patient gender, by Highest Total Prescription Volume, 2023-24
Section 85 and Section 100, excluding Doctors' Bag and including under co-payment prescriptions

Age Group	Females				Males			
	Drug Name	Prescriptions			Drug Name	Prescriptions		
		PBS Subsidised	Under Co-Payment	Total		PBS Subsidised	Under Co-Payment	Total
Under 18 years old	AMOXICILLIN	193,613	598,198	791,811	METHYLPHENIDATE	782,496	119,680	902,176
	CEFALEXIN	115,843	349,401	465,244	AMOXICILLIN	213,494	643,295	856,789
	METHYLPHENIDATE	299,298	51,498	350,796	CEFALEXIN	107,138	317,908	425,046
	FLUOXETINE	120,718	200,487	321,205	LISDEXAMFETAMINE	366,584	31	366,615
	PREDNISOLONE SODIUM PHOSPHATE	58,612	196,169	254,781	PREDNISOLONE SODIUM PHOSPHATE	85,251	280,495	365,746
	SALBUTAMOL	82,559	109,979	192,538	GUANFACINE	346,091	52	346,143
	SERTRALINE	60,543	116,480	177,023	SALBUTAMOL	113,283	147,610	260,893
	LISDEXAMFETAMINE	172,542	15	172,557	FLUOXETINE	123,481	114,798	238,279
	AMOXICILLIN + CLAVULANIC ACID	42,958	125,056	168,014	FLUTICASON PROPRIONATE	68,557	148,648	217,205
	LEVONORGESTREL + ETHINYLESTRADIOL	40,814	108,715	149,529	AMOXICILLIN + CLAVULANIC ACID	49,748	143,638	193,386
TOTAL	1,187,500	1,855,998	3,043,498	TOTAL	2,256,123	1,916,155	4,172,278	
18-39 years old	SERTRALINE	333,314	1,029,180	1,362,494	ESCITALOPRAM	130,578	516,991	647,569
	ESCITALOPRAM	283,553	1,015,546	1,299,099	SERTRALINE	135,048	387,797	522,845
	LEVONORGESTREL + ETHINYLESTRADIOL	152,318	707,911	860,229	AMOXICILLIN	66,791	341,569	408,360
	AMOXICILLIN	164,329	512,393	676,722	CEFALEXIN	57,608	265,396	323,004
	CEFALEXIN	153,778	500,126	653,904	LISDEXAMFETAMINE	311,001	10	311,011
	FLUOXETINE	195,047	424,682	619,729	PANTOPRAZOLE	96,315	207,905	304,220
	VENLAFAXINE	162,051	296,843	458,894	AMOXICILLIN + CLAVULANIC ACID	57,510	244,273	301,783
	AMOXICILLIN + CLAVULANIC ACID	118,171	316,469	434,640	FLUOXETINE	110,112	173,103	283,215
	DESVENLAFAXINE	164,460	262,701	427,161	MIRTAZAPINE	117,197	154,453	271,650
	LISDEXAMFETAMINE	404,866	16	404,882	DOXYCYCLINE	45,261	216,803	262,064
TOTAL	2,131,887	5,065,867	7,197,754	TOTAL	1,127,421	2,508,300	3,635,721	
40-59 years old	ROSUVASTATIN	482,371	1,066,592	1,548,963	ROSUVASTATIN	436,915	1,757,886	2,194,801
	ESCITALOPRAM	332,813	1,037,034	1,369,847	ATORVASTATIN	363,148	954,539	1,317,687
	PANTOPRAZOLE	506,872	741,866	1,248,738	PANTOPRAZOLE	366,985	702,691	1,069,676
	SERTRALINE	328,217	893,145	1,221,362	PERINDOPRIL	227,113	768,290	995,403
	ESOMEPRAZOLE	387,521	561,668	949,189	METFORMIN	263,908	595,486	859,394
	VENLAFAXINE	341,404	585,065	926,469	ESOMEPRAZOLE	241,859	538,225	780,084
	ATORVASTATIN	331,132	526,842	857,974	ESCITALOPRAM	171,153	605,574	776,727
	METFORMIN	294,063	469,154	763,217	SERTRALINE	167,393	448,549	615,942
	PERINDOPRIL	222,085	536,248	758,333	PERINDOPRIL + AMLODIPINE	111,831	490,781	602,612
	ESTRADIOL	115,105	629,798	744,903	TELMISARTAN	87,516	471,875	559,391
TOTAL	3,341,583	7,047,412	10,388,995	TOTAL	2,437,821	7,333,896	9,771,717	
60+ years old	ROSUVASTATIN	4,819,266	1,671,872	6,491,138	ROSUVASTATIN	3,975,536	2,224,453	6,199,989
	ATORVASTATIN	3,503,319	891,429	4,394,748	ATORVASTATIN	3,518,012	1,398,577	4,916,589
	PANTOPRAZOLE	3,438,151	724,278	4,162,429	PANTOPRAZOLE	2,626,777	789,972	3,416,749
	ESOMEPRAZOLE	2,920,119	605,744	3,525,863	PERINDOPRIL	1,736,621	837,143	2,573,764
	PERINDOPRIL	1,773,950	557,225	2,331,175	ESOMEPRAZOLE	1,784,857	579,554	2,364,411
	AMLODIPINE	1,653,952	400,865	2,054,817	METFORMIN	1,571,342	648,083	2,219,425
	IRBESARTAN	1,445,379	384,801	1,830,180	DUTASTERIDE + TAMISULOSIN	1,814,214	225,616	2,039,830
	TELMISARTAN	1,351,019	450,162	1,801,181	APIXABAN	1,924,655	126	1,924,781
	CANDESARTAN	1,367,106	427,242	1,794,348	AMLODIPINE	1,284,252	547,457	1,831,709
	APIXABAN	1,790,475	106	1,790,581	TELMISARTAN	932,797	531,204	1,464,001
TOTAL	24,062,736	6,113,724	30,176,460	TOTAL	21,169,063	7,782,185	28,951,248	


Approximately 1.1% of all prescriptions are excluded due to unknown patient demographic details.
Reported gender in the PBS Online Claims Data is sourced from Services Australia.
Department of Health and Aged Care does not have access to Medicare personal records.

Figure 2: Total Government Cost by gender and age-groups, 2023-24
 Section 85 and Section 100 excluding Doctors' Bag


Total Government Cost by Gender



Government Cost by Gender and Age-Groups



Government Cost by Age-Groups




Approximately 1.1% of all prescriptions are excluded due to unknown patient demographic details.
 Reported gender in the PBS Online Claims Data is sourced from Services Australia.
 Department of Health and Aged Care does not have access to Medicare personal records.


The Source of the data is from Table 6(c): PBS prescriptions per age group and patient gender, by Highest Total Prescription Volume, 2023-24

Figure 3: Total PBS prescriptions by gender and age-groups, 2023-24
 Section 85 and Section 100, including under co-payment and excluding Doctors' Bag


Total PBS Prescriptions by Gender




Total PBS Prescriptions by Gender and Age-Groups



PBS Subsidised Prescriptions by Gender and Age-Groups



Under Co-Payment Prescriptions by Gender and Age-Groups



The Source of the data is from Table 6(c): PBS prescriptions per age group and patient gender, by Highest Total Prescription Volume, 2023-24

Figure 4: PBS prescriptions dispensed in a Residential Aged Care Facility (RACF), 2023-24

Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions




Table 6(c): PBS prescriptions per age group and patient gender, 2023-24

Section 85 and Section 100, excluding Doctors' Bag and including under co-payment prescriptions

Age Group	Patient Gender	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Government Cost
Under 18 years old	Female	2,553,236	3,204,826	5,758,062	\$328,956,812
Under 18 years old	Male	3,664,676	3,128,341	6,793,017	\$404,298,964
18-39 years old	Female	9,364,923	11,730,077	21,095,000	\$1,293,563,664
18-39 years old	Male	5,937,586	7,035,223	12,972,809	\$1,046,706,786
40-59 years old	Female	19,298,214	21,223,461	40,521,675	\$2,187,417,546
40-59 years old	Male	15,329,664	19,606,358	34,936,022	\$1,838,906,914
60+ years old	Female	92,950,158	18,242,891	111,193,049	\$5,141,085,756
60+ years old	Male	76,533,411	21,226,901	97,760,312	\$5,311,370,475

Approximately 1.1% of all prescriptions are excluded due to unknown patient demographic details.

Reported gender in the PBS Online Claims Data is sourced from Services Australia.

Department of Health and Aged Care does not have access to Medicare personal records.

Table 6(d): PBS prescriptions dispensed in a Residential Aged Care Facility, 2023-24

Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions

State	PBS Prescriptions	Percentage
NSW	4,394,824	35.5%
VIC	3,042,964	24.6%
QLD	2,440,439	19.7%
SA	1,111,839	9.0%
WA	908,153	7.3%
TAS	264,531	2.1%
NT	20,400	0.2%
ACT	186,096	1.5%
Australia	12,369,246	100.0%

PBS Expenditure and Prescriptions 2023-24

Table 6(e): Top 10 PBS Drugs (Generic Name) by Highest Government Cost, dispensed in a Residential Aged Care Facility, 2023-24
Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions

Rank	Drug Name	PBS Prescriptions	Government Cost	Patient Contribution*	Total Cost**
1	MOLNUPIRAVIR	52,624	\$57,605,149	\$395,751	\$58,000,900
2	APIXABAN	281,318	\$23,708,748	\$1,839,640	\$25,548,388
3	DENOSUMAB	71,670	\$17,714,571	\$517,652	\$18,232,223
4	BUPRENORPHINE	443,578	\$12,492,928	\$1,955,073	\$14,448,002
5	LEVODOPA + CARBIDOPA	59,299	\$11,008,234	\$357,829	\$11,366,063
6	NIRMATRELVIR (&) RITONAVIR	9,559	\$10,578,967	\$79,991	\$10,658,958
7	OXYCODONE + NALOXONE	229,630	\$7,316,616	\$996,269	\$8,312,885
8	PANTOPRAZOLE	573,404	\$6,909,766	\$2,376,362	\$9,286,128
9	RIVAROXABAN	119,401	\$6,731,189	\$757,880	\$7,489,068
10	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	404,253	\$6,111,390	\$1,519,091	\$7,630,480

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

Table 6(f): Top 10 PBS Drugs (Generic Name) by Highest Prescriptions, dispensed in a Residential Aged Care Facility, 2023-24
Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions

Rank	Drug Name	PBS Prescriptions	Government Cost	Patient Contribution*	Total Cost**
1	PANTOPRAZOLE	573,404	\$6,909,766	\$2,376,362	\$9,286,128
2	BUPRENORPHINE	443,578	\$12,492,928	\$1,955,073	\$14,448,002
3	PARACETAMOL	410,148	\$5,361,340	\$1,385,658	\$6,746,998
4	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	404,253	\$6,111,390	\$1,519,091	\$7,630,480
5	MIRTAZAPINE	333,437	\$3,841,451	\$1,218,141	\$5,059,592
6	ATORVASTATIN	329,099	\$3,750,080	\$1,236,989	\$4,987,069
7	APIXABAN	281,318	\$23,708,748	\$1,839,640	\$25,548,388
8	FUROSEMIDE	264,631	\$3,110,028	\$951,852	\$4,061,880
9	ROSUVASTATIN	238,826	\$2,748,582	\$891,645	\$3,640,226
10	OXYCODONE + NALOXONE	229,630	\$7,316,616	\$996,269	\$8,312,885

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS (S85 + S100) subsidised prescriptions.

PBS Expenditure and Prescriptions 2023-24

Table 7: Top 50 ATC Level 2 Drug Groups by Highest Total Prescription Volume, 2023-24
Section 85 and Section 100, including Doctors' Bag and under co-payment prescriptions

Rank	ATC Level 2 Code	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	23,873,184	16,014,182	39,887,366
2	N06	PSYCHOANALEPTICS	21,447,109	17,124,994	38,572,103
3	C10	LIPID MODIFYING AGENTS	24,268,982	13,743,077	38,012,059
4	A02	DRUGS FOR ACID RELATED DISORDERS	16,385,133	7,789,242	24,174,375
5	J01	ANTIBACTERIALS FOR SYSTEMIC USE	9,717,415	12,771,999	22,489,414
6	A10	DRUGS USED IN DIABETES	18,099,705	2,944,671	21,044,376
7	N02	ANALGESICS	15,046,024	5,217,495	20,263,519
8	R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	11,743,299	1,458,698	13,201,997
9	B01	ANTITHROMBOTIC AGENTS	10,449,907	878,445	11,328,352
10	C07	BETA BLOCKING AGENTS	6,960,937	2,642,399	9,603,336
11	S01	OPHTHALMOLOGICALS	7,766,270	1,770,831	9,537,101
12	C08	CALCIUM CHANNEL BLOCKERS	6,397,436	2,885,182	9,282,618
13	N05	PSYCHOLEPTICS	6,720,921	1,905,723	8,626,644
14	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,297,890	3,239,459	6,537,349
15	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	2,458,564	2,910,354	5,368,918
16	H02	CORTICOSTEROIDS FOR SYSTEMIC USE	2,167,208	2,203,477	4,370,685
17	D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,400,958	1,761,930	4,162,888
18	C01	CARDIAC THERAPY	2,972,511	620,375	3,592,886
19	N03	ANTI-EPILEPTICS	2,763,446	774,622	3,538,068
20	C03	DIURETICS	2,548,900	649,857	3,198,757
21	C02	ANTI-HYPERTENSIVES	2,308,737	706,932	3,015,669
22	G04	UROLOGICALS	2,445,745	372,886	2,818,631
23	L04	IMMUNOSUPPRESSANTS	2,405,193	120,136	2,525,329
24	M04	ANTI-GOUT PREPARATIONS	1,359,992	992,931	2,352,923
25	M05	DRUGS FOR TREATMENT OF BONE DISEASES	2,191,610	113,778	2,305,388
26	H03	THYROID THERAPY	1,300,181	1,002,574	2,302,755
27	L01	ANTI-NEOPLASTIC AGENTS	2,167,285	111,297	2,278,582
28	J05	ANTIVIRALS FOR SYSTEMIC USE	1,675,722	553,411	2,229,133
29	N04	ANTI-PARKINSON DRUGS	1,568,024	194,235	1,762,259
30	A06	DRUGS FOR CONSTIPATION	1,393,544	107,008	1,500,552
31	B03	ANTI-ANEMIC PREPARATIONS	1,194,130	137,858	1,331,988
32	A04	ANTIEMETICS AND ANTINAUSEANTS	859,706	461,045	1,320,751
33	L02	ENDOCRINE THERAPY	913,951	342,999	1,256,950
34	N07	OTHER NERVOUS SYSTEM DRUGS	1,138,063	32,787	1,170,850
35	A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	748,434	358,051	1,106,485
36	S02	OTOLOGICALS	497,917	510,218	1,008,135
37	A07	ANTI-DIARRHEALS, INTESTINAL ANTI-INFLAMMATORY/ANTI-INFECTIVE AGENTS	952,225	44,939	997,164
38	D10	ANTI-ACNE PREPARATIONS	394,796	59,494	454,290
39	M03	MUSCLE RELAXANTS	361,971	63,362	425,333
40	A12	MINERAL SUPPLEMENTS	363,822	55,754	419,576
41	D11	OTHER DERMATOLOGICAL PREPARATIONS	342,050	68,658	410,708
42	D05	ANTI-PSORIASIS	333,927	5,347	339,274
43	G02	OTHER GYNECOLOGICALS	229,197	4,064	233,261
44	A09	DIGESTIVES, INCL. ENZYMES	215,930	150	216,080
45	A11	VITAMINS	161,875	43,123	204,998
46	B02	ANTIHEMORRHAGICS	182,368	17,264	199,632
47	H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	188,147	100	188,247
48	L03	IMMUNOSTIMULANTS	167,056	885	167,941
49	V03	ALL OTHER THERAPEUTIC PRODUCTS	119,910	6,671	126,581
50	A01	STOMATOLOGICAL PREPARATIONS	79,882	45,978	125,860

The Anatomical Therapeutic Chemical code (ATC) is an international classification for medicines developed by the World Health Organisation and used in the PBS Schedule and referred to as Body Systems. <https://www.pbs.gov.au/browse/body-system>

PBS Expenditure and Prescriptions 2023-24

Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2022-23 and 2023-24
Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution*			
	2022-23	2023-24	Prescriptions Change	Percentage Change	2022-23	2023-24	Gov Cost Change	Percentage Change	2022-23	2023-24	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	37,521,185	39,330,362	1,809,177	4.8%	\$1,296,607,530	\$1,484,786,830	\$188,179,300	14.5%	\$290,407,700	\$305,460,159	\$15,052,459	5.2%
BLOOD AND BLOOD FORMING ORGANS	11,615,896	11,828,936	213,040	1.8%	\$944,217,916	\$987,897,120	\$43,679,204	4.6%	\$118,859,381	\$116,143,806	-\$2,715,575	-2.3%
CARDIOVASCULAR SYSTEM	70,873,119	69,332,757	-1,540,362	-2.2%	\$1,223,349,202	\$1,287,646,771	\$64,297,570	5.3%	\$347,838,687	\$356,746,242	\$8,907,555	2.6%
DERMATOLOGICALS	3,282,753	3,565,234	282,481	8.6%	\$340,238,589	\$443,298,416	\$103,059,827	30.3%	\$36,608,373	\$42,630,698	\$6,022,325	16.5%
GENITO URINARY SYSTEM AND SEX HORMONES	4,895,708	5,133,506	237,798	4.9%	\$316,418,220	\$314,756,501	-\$1,661,719	-0.5%	\$49,020,974	\$51,543,607	\$2,522,633	5.1%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,728,395	3,757,990	29,595	0.8%	\$176,227,006	\$162,668,275	-\$13,558,731	-7.7%	\$23,334,785	\$24,814,902	\$1,480,117	6.3%
ANTIINFECTIVES FOR SYSTEMIC USE	11,487,595	11,512,874	25,279	0.2%	\$1,726,264,210	\$1,476,811,910	-\$249,452,300	-14.5%	\$82,832,798	\$81,791,646	-\$1,041,152	-1.3%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	5,297,156	5,653,485	356,329	6.7%	\$6,581,061,256	\$7,225,980,407	\$644,919,151	9.8%	\$78,211,805	\$77,247,873	-\$963,932	-1.2%
MUSCULO-SKELETAL SYSTEM	7,119,115	7,213,197	94,082	1.3%	\$591,379,259	\$664,137,896	\$72,758,638	12.3%	\$45,821,170	\$49,227,583	\$3,406,413	7.4%
NERVOUS SYSTEM	46,813,195	48,706,282	1,893,087	4.0%	\$1,383,346,289	\$1,554,089,294	\$170,743,004	12.3%	\$303,467,943	\$345,762,135	\$42,294,192	13.9%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	70,471	93,894	23,423	33.2%	\$3,582,398	\$4,621,269	\$1,038,871	29.0%	\$617,807	\$1,064,612	\$446,805	72.3%
RESPIRATORY SYSTEM	12,156,245	11,833,956	-322,289	-2.7%	\$1,245,800,172	\$1,286,669,160	\$40,868,988	3.3%	\$140,625,310	\$127,917,393	-\$12,707,917	-9.0%
SENSORY ORGANS	8,014,937	8,276,344	261,407	3.3%	\$826,924,409	\$788,104,898	-\$38,819,511	-4.7%	\$43,240,677	\$47,704,631	\$4,463,954	10.3%
VARIOUS	184,747	186,951	2,204	1.2%	\$59,289,291	\$57,570,747	-\$1,718,544	-2.9%	\$2,953,708	\$2,573,000	-\$380,708	-12.9%
UNLESS OTHERWISE CLASSIFIED	89,684	82,841	-6,843	-7.6%	\$3,386,366	\$3,482,163	\$95,797	2.8%	\$581,739	\$572,154	-\$9,585	-1.6%
TOTAL	223,150,201	226,508,609	3,358,408	1.5%	\$16,718,092,113	\$17,742,521,656	\$1,024,429,543	6.1%	\$1,564,422,856	\$1,631,200,439	\$66,777,583	4.3%

ATC Group Level 1	Total Cost**				Average Price***			
	2022-23	2023-24	Total Cost Change	Percentage Change	2022-23	2023-24	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$1,587,015,230	\$1,790,246,989	\$203,231,758	12.8%	\$42.30	\$45.52	\$3.22	7.6%
BLOOD AND BLOOD FORMING ORGANS	\$1,063,077,297	\$1,104,040,926	\$40,963,629	3.9%	\$91.52	\$93.33	\$1.81	2.0%
CARDIOVASCULAR SYSTEM	\$1,571,187,889	\$1,644,393,013	\$73,205,125	4.7%	\$22.17	\$23.72	\$1.55	7.0%
DERMATOLOGICALS	\$376,846,962	\$485,929,114	\$109,082,151	28.9%	\$114.80	\$136.30	\$21.50	18.7%
GENITO URINARY SYSTEM AND SEX HORMONES	\$365,439,194	\$366,300,108	\$860,914	0.2%	\$74.64	\$71.35	-\$3.29	-4.4%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$199,561,791	\$187,483,177	-\$12,078,614	-6.1%	\$53.52	\$49.89	-\$3.63	-6.8%
ANTIINFECTIVES FOR SYSTEMIC USE	\$1,809,097,008	\$1,558,603,556	-\$250,493,452	-13.8%	\$157.48	\$135.38	-\$22.10	-14.0%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$6,659,273,061	\$7,303,228,279	\$643,955,219	9.7%	\$1,257.14	\$1,291.81	\$34.67	2.8%
MUSCULO-SKELETAL SYSTEM	\$637,200,428	\$713,365,479	\$76,165,051	12.0%	\$89.51	\$98.90	\$9.39	10.5%
NERVOUS SYSTEM	\$1,686,814,232	\$1,899,851,428	\$213,037,196	12.6%	\$36.03	\$39.01	\$2.98	8.3%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$4,200,204	\$5,685,880	\$1,485,676	35.4%	\$59.60	\$60.56	\$0.96	1.6%
RESPIRATORY SYSTEM	\$1,386,425,482	\$1,414,586,553	\$28,161,071	2.0%	\$114.05	\$119.54	\$5.49	4.8%
SENSORY ORGANS	\$870,165,086	\$835,809,529	-\$34,355,557	-3.9%	\$108.57	\$100.99	-\$7.58	-7.0%
VARIOUS	\$62,242,999	\$60,143,747	-\$2,099,252	-3.4%	\$336.91	\$321.71	-\$15.20	-4.5%
UNLESS OTHERWISE CLASSIFIED	\$3,968,106	\$4,054,317	\$86,212	2.2%	\$44.25	\$48.94	\$4.69	10.6%
TOTAL	\$18,282,514,969	\$19,373,722,095	\$1,091,207,126	6.0%	\$81.93	\$85.53	\$3.60	4.4%


* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

Figure 5(a): Percentages of subsidised prescriptions for ATC main groups, 2023-24


Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions



ATC A: ALIMENTARY TRACT AND METABOLISM	ATC B: BLOOD AND BLOOD FORMING ORGANS
ATC C: CARDIOVASCULAR SYSTEM	ATC D: DERMATOLOGICALS
ATC G: GENITO URINARY SYSTEM AND SEX HORMONES	ATC H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
ATC J: ANTIINFECTIVES FOR SYSTEMIC USE	ATC L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ATC M: MUSCULO-SKELETAL SYSTEM	ATC N: NERVOUS SYSTEM
ATC R: RESPIRATORY SYSTEM	ATC S: SENSORY ORGANS
Others: ATC - P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS, and ATC V: VARIOUS	

The Source of the data is from Table 8(a) ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2022-23 and 2023-24

Figure 5(b): Percentages of Government Cost for ATC main groups, 2023-24
 Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions



ATC A: ALIMENTARY TRACT AND METABOLISM	ATC B: BLOOD AND BLOOD FORMING ORGANS
ATC C: CARDIOVASCULAR SYSTEM	ATC D: DERMATOLOGICALS
ATC G: GENITO URINARY SYSTEM AND SEX HORMONES	ATC H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
ATC J: ANTIINFECTIVES FOR SYSTEMIC USE	ATC L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ATC M: MUSCULO-SKELETAL SYSTEM	ATC N: NERVOUS SYSTEM
ATC R: RESPIRATORY SYSTEM	ATC S: SENSORY ORGANS
Others: ATC - P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS, and ATC V: VARIOUS	

The Source of the data is from Table 8(a) ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2022-23 and 2023-24

PBS Expenditure and Prescriptions 2023-24

Table 9(a): Top 35 Drugs by Highest Change to Government Cost, 2022-23 and 2023-24
Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions

Rank	Drug Name	2022-23					2023-24					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***		
1	SEMAGLUTIDE	1,255,063	\$146,130,399	\$20,905,210	\$167,035,610	\$133	2,397,521	\$284,633,101	\$36,471,199	\$321,104,299	\$134	\$138,502,701	94.78%
2	PEMBROLIZUMAB	52,663	\$447,023,658	\$227,317	\$447,250,975	\$8,493	66,560	\$566,997,047	\$299,405	\$567,296,452	\$8,523	\$119,973,389	26.84%
3	DUPILUMAB	151,145	\$258,802,303	\$4,020,019	\$262,822,322	\$1,739	213,318	\$366,173,611	\$4,994,865	\$371,168,476	\$1,740	\$107,371,308	41.49%
4	FARICIMAB	32,839	\$35,916,476	\$438,065	\$36,354,541	\$1,107	116,842	\$124,764,100	\$1,555,925	\$126,320,024	\$1,081	\$88,847,624	247.37%
5	USTEKINUMAB	48,843	\$355,865,621	\$1,300,007	\$357,165,629	\$7,313	60,131	\$435,514,789	\$1,404,238	\$436,919,027	\$7,266	\$79,649,168	22.38%
6	ELEXACFTOR + TEZACFTOR + IVACFTOR (&) IVACFTOR	24,007	\$512,836,185	\$377,471	\$513,213,656	\$21,378	26,587	\$568,268,710	\$367,331	\$568,636,041	\$21,388	\$55,432,525	10.81%
7	UPADACITINIB	122,468	\$158,315,349	\$2,705,044	\$161,020,393	\$1,315	150,669	\$211,184,905	\$3,162,517	\$214,347,422	\$1,423	\$52,869,555	33.40%
8	ZANUBRUTINIB	3,014	\$26,376,689	\$37,217	\$26,413,906	\$8,764	9,625	\$76,824,608	\$118,419	\$76,943,028	\$7,994	\$50,447,920	191.26%
9	CEMIPLIMAB	7,980	\$59,572,936	\$30,980	\$59,603,916	\$7,469	14,419	\$107,712,803	\$42,711	\$107,755,514	\$7,473	\$48,139,867	80.81%
10	DARATUMUMAB	18,750	\$135,263,023	\$258,228	\$135,521,251	\$7,228	25,597	\$182,995,797	\$352,877	\$183,348,674	\$7,163	\$47,732,774	35.29%
11	BUPRENORPHINE	1,198,102	\$48,351,855	\$6,633,189	\$54,985,044	\$46	1,379,299	\$94,585,564	\$10,226,497	\$104,812,060	\$76	\$46,233,708	95.62%
12	DURVALUMAB	8,898	\$71,422,631	\$38,187	\$71,460,818	\$8,031	10,752	\$113,444,508	\$56,484	\$113,500,992	\$10,556	\$42,021,876	58.84%
13	ENZALUTAMIDE	34,068	\$119,709,194	\$365,794	\$120,074,988	\$3,525	45,672	\$157,994,896	\$504,502	\$158,499,398	\$3,470	\$38,285,702	31.98%
14	BUROSUMAB	1,342	\$29,641,632	\$32,019	\$29,673,650	\$22,112	3,058	\$64,955,831	\$69,154	\$65,024,986	\$21,264	\$35,314,200	119.14%
15	DAROLUTAMIDE	6,761	\$23,653,223	\$78,974	\$23,732,197	\$3,510	16,824	\$58,919,406	\$229,036	\$59,148,442	\$3,516	\$35,266,183	149.10%
16	LISDEXAMFETAMINE	1,173,680	\$86,091,959	\$29,804,670	\$115,896,629	\$99	1,542,855	\$119,683,727	\$36,433,831	\$156,117,558	\$101	\$33,591,768	39.02%
17	APIXABAN	3,718,182	\$304,413,459	\$39,412,512	\$343,825,971	\$92	4,043,526	\$336,135,202	\$40,193,026	\$376,328,229	\$93	\$31,721,743	10.42%
18	APALUTAMIDE	475	\$1,757,868	\$5,918	\$1,763,786	\$3,713	9,017	\$33,282,301	\$124,326	\$33,406,626	\$3,705	\$31,524,432	1,793.33%
19	OFATUMUMAB	15,213	\$36,675,480	\$390,353	\$37,065,833	\$2,436	26,983	\$63,517,231	\$618,205	\$64,135,435	\$2,377	\$26,841,751	73.19%
20	NIVOLUMAB	56,074	\$411,508,391	\$246,257	\$411,754,649	\$7,343	60,573	\$437,624,544	\$233,625	\$437,858,169	\$7,229	\$26,116,152	6.35%
21	FREMANEZUMAB	68,073	\$36,374,901	\$1,684,131	\$38,059,033	\$559	113,587	\$61,061,513	\$2,536,944	\$63,598,457	\$560	\$24,686,612	67.87%
22	SACUBITRIL + VALSARTAN	661,377	\$120,546,199	\$7,815,883	\$128,362,082	\$194	765,411	\$144,704,947	\$8,499,974	\$153,204,921	\$200	\$24,158,748	20.04%
23	GUSELKUMAB	33,024	\$124,489,786	\$869,848	\$125,359,634	\$3,796	39,868	\$148,534,932	\$918,211	\$149,453,143	\$3,749	\$24,045,146	19.31%
24	RISANKIZUMAB	13,778	\$73,966,791	\$378,356	\$74,345,147	\$5,396	18,110	\$97,369,950	\$438,882	\$97,808,832	\$5,401	\$23,403,159	31.64%
25	VEDOLIZUMAB	52,244	\$130,742,690	\$1,517,995	\$132,260,685	\$2,532	63,372	\$153,355,936	\$1,604,028	\$154,959,963	\$2,445	\$22,613,246	17.30%
26	DAPAGLIFLOZIN	1,069,523	\$46,766,294	\$14,034,855	\$60,801,148	\$57	1,525,456	\$69,331,927	\$18,237,581	\$87,569,508	\$57	\$22,565,633	48.25%
27	RUXOLITINIB	16,783	\$77,904,492	\$230,723	\$78,135,215	\$4,656	21,305	\$97,369,241	\$290,079	\$97,659,321	\$4,584	\$19,464,749	24.99%
28	MEPOLIZUMAB	27,046	\$42,774,378	\$504,813	\$43,279,191	\$1,600	38,984	\$61,683,206	\$731,002	\$62,414,208	\$1,601	\$18,908,827	44.21%
29	DENOSUMAB	1,084,042	\$272,795,409	\$11,637,442	\$284,432,852	\$262	1,154,845	\$291,440,721	\$11,559,074	\$302,999,794	\$262	\$18,645,311	6.83%
30	EMPAGLIFLOZIN	1,460,990	\$67,942,866	\$19,816,465	\$87,759,331	\$60	1,751,194	\$85,709,218	\$21,561,843	\$107,271,061	\$61	\$17,766,352	26.15%
31	OSIMERTINIB	18,401	\$146,131,593	\$330,697	\$146,462,290	\$7,959	20,842	\$163,467,414	\$335,331	\$163,802,746	\$7,859	\$17,335,821	11.86%
32	VOSORITIDE	15	\$393,436	\$405	\$393,841	\$26,256	634	\$17,514,898	\$12,909	\$17,527,807	\$27,646	\$17,121,462	4,351.77%
33	ASCIMINIB	226	\$1,541,529	\$3,844	\$1,545,373	\$6,838	2,595	\$17,962,548	\$40,004	\$18,002,552	\$6,937	\$16,421,020	1,065.24%
34	RIBOCICLIB	17,599	\$79,821,674	\$310,191	\$80,131,865	\$4,553	21,124	\$94,929,668	\$351,727	\$95,281,395	\$4,511	\$15,107,994	18.93%
35	ABEMACICLIB	7,578	\$31,888,111	\$136,499	\$32,024,610	\$4,226	11,002	\$46,317,975	\$185,883	\$46,503,858	\$4,227	\$14,429,864	45.25%

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

PBS Expenditure and Prescriptions 2023-24

Table 9(b): Top 35 Drugs by Highest Change to Subsidised Script Volume, 2022-23 and 2023-24
Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions

Rank	Drug Name	2022-23					2023-24					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***	PBS Subsidised Prescriptions	Government Cost	Patient Contribution*	Total Cost**	Ave. Price***		
1	SEMAGLUTIDE	1,255,063	\$146,130,399	\$20,905,210	\$167,035,610	\$133.09	2,397,521	\$284,633,101	\$36,471,199	\$321,104,299	\$133.93	1,142,458	91.03%
2	DAPAGLIFLOZIN	1,069,523	\$46,766,294	\$14,034,855	\$60,801,148	\$56.85	1,525,456	\$69,331,927	\$18,237,581	\$87,569,508	\$57.41	455,933	42.63%
3	LISDEXAMFETAMINE	1,173,680	\$86,091,959	\$29,804,670	\$115,896,629	\$98.75	1,542,855	\$119,683,727	\$36,433,831	\$156,117,558	\$101.19	369,175	31.45%
4	APIXABAN	3,718,182	\$304,413,459	\$39,412,512	\$343,825,971	\$92.47	4,043,526	\$336,135,202	\$40,193,026	\$376,328,229	\$93.07	325,344	8.75%
5	METHYLPHENIDATE	1,136,591	\$41,320,502	\$20,912,426	\$62,232,928	\$54.75	1,438,540	\$49,526,996	\$26,251,905	\$75,778,900	\$52.68	301,949	26.57%
6	EMPAGLIFLOZIN	1,460,990	\$67,942,866	\$19,816,465	\$87,759,331	\$60.07	1,751,194	\$85,709,218	\$21,561,843	\$107,271,061	\$61.26	290,204	19.86%
7	METHADONE	57,790	\$2,811,326	\$375,554	\$3,186,881	\$55.15	314,415	\$8,866,134	\$2,686,509	\$11,552,643	\$36.74	256,625	444.06%
8	PANTOPRAZOLE	6,951,325	\$74,514,366	\$30,767,768	\$105,282,133	\$15.15	7,206,109	\$83,593,296	\$33,295,466	\$116,888,762	\$16.22	254,784	3.67%
9	BUPRENORPHINE	1,198,102	\$48,351,855	\$6,633,189	\$54,985,044	\$45.89	1,379,299	\$94,585,564	\$10,226,497	\$104,812,060	\$75.99	181,197	15.12%
10	HYALURONATE SODIUM	667,814	\$19,923,010	\$3,143,393	\$23,066,403	\$34.54	837,786	\$24,444,847	\$4,464,571	\$28,909,418	\$34.51	169,972	25.45%
11	BECLOMETASONE + FORMOTEROL + GLYCOPYRRONIUM	128,363	\$9,824,758	\$1,120,248	\$10,945,006	\$85.27	283,136	\$20,117,279	\$2,673,655	\$22,790,933	\$80.49	154,773	120.57%
12	DEXAMFETAMINE	316,747	\$6,126,789	\$4,842,693	\$10,969,482	\$34.63	457,810	\$8,276,115	\$8,228,167	\$16,504,281	\$36.05	141,063	44.53%
13	DUTASTERIDE + TAMSULOSIN	1,734,927	\$41,702,240	\$10,238,440	\$51,940,680	\$29.94	1,862,651	\$46,414,706	\$11,190,049	\$57,604,755	\$30.93	127,724	7.36%
14	FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL	740,860	\$58,916,608	\$6,909,408	\$65,826,016	\$88.85	866,766	\$69,999,435	\$8,094,190	\$78,093,625	\$90.10	125,906	16.99%
15	OXYCODONE + NALOXONE	1,217,718	\$48,606,732	\$8,683,159	\$57,289,892	\$47.05	1,331,954	\$52,490,683	\$10,366,212	\$62,856,894	\$47.19	114,236	9.38%
16	GUANFACINE	410,198	\$45,160,770	\$7,075,221	\$52,235,991	\$127.34	521,422	\$34,245,097	\$8,574,768	\$42,819,865	\$82.12	111,224	27.11%
17	EMPAGLIFLOZIN + METFORMIN	1,075,437	\$49,732,869	\$17,868,839	\$67,601,708	\$62.86	1,184,593	\$58,017,589	\$17,888,451	\$75,906,040	\$64.08	109,156	10.15%
18	SACUBITRIL + VALSARTAN	661,377	\$120,546,199	\$7,815,883	\$128,362,082	\$194.08	765,411	\$144,704,947	\$8,499,974	\$153,204,921	\$200.16	104,034	15.73%
19	EZETIMIBE	1,182,973	\$19,758,822	\$5,036,747	\$24,795,569	\$20.96	1,280,368	\$19,617,319	\$5,608,295	\$25,225,614	\$19.70	97,395	8.23%
20	ROSUVASTATIN	9,709,339	\$107,255,802	\$46,773,524	\$154,029,326	\$15.86	9,806,213	\$117,660,751	\$48,640,480	\$166,301,231	\$16.96	96,874	1.00%
21	AMOXICILLIN	1,715,687	\$17,338,624	\$9,518,022	\$26,856,646	\$15.65	1,808,003	\$20,052,580	\$10,547,256	\$30,599,836	\$16.92	92,316	5.38%
22	MIRTAZAPINE	2,345,047	\$27,917,854	\$10,314,994	\$38,232,849	\$16.30	2,429,311	\$30,534,564	\$11,083,623	\$41,618,187	\$17.13	84,264	3.59%
23	FARICIMAB	32,839	\$35,916,476	\$438,065	\$36,354,541	\$1,107.05	116,842	\$124,764,100	\$1,555,925	\$126,320,024	\$1,081.12	84,003	255.80%
24	TAPENTADOL	1,137,587	\$39,198,556	\$8,147,835	\$47,346,391	\$41.62	1,216,401	\$42,171,727	\$9,596,874	\$51,768,601	\$42.56	78,814	6.93%
25	RISEDRONATE	577,314	\$16,682,997	\$4,659,707	\$21,342,704	\$36.97	653,777	\$16,381,195	\$7,167,940	\$23,549,136	\$36.02	76,463	13.24%
26	BISOPROLOL	1,741,020	\$25,992,892	\$7,273,438	\$33,266,330	\$19.11	1,815,707	\$25,596,572	\$7,789,281	\$33,385,854	\$18.39	74,687	4.29%
27	EZETIMIBE + ATORVASTATIN	669,165	\$13,228,067	\$3,006,918	\$16,234,985	\$24.26	742,481	\$13,715,315	\$3,768,830	\$17,484,145	\$23.55	73,316	10.96%
28	PARACETAMOL	1,740,594	\$26,767,142	\$5,710,265	\$32,477,407	\$18.66	1,811,452	\$29,112,845	\$6,165,809	\$35,278,654	\$19.48	70,858	4.07%
29	DENOSUMAB	1,084,042	\$272,795,409	\$11,637,442	\$284,432,852	\$262.38	1,154,845	\$291,440,721	\$11,559,074	\$302,999,794	\$262.37	70,803	6.53%
30	ESCITALOPRAM	2,412,687	\$24,767,158	\$12,469,980	\$37,237,137	\$15.43	2,481,531	\$27,404,735	\$13,472,939	\$40,877,673	\$16.47	68,844	2.85%
31	SERTRALINE	2,448,117	\$25,581,624	\$12,397,850	\$37,979,473	\$15.51	2,515,979	\$28,467,851	\$13,461,119	\$41,928,970	\$16.67	67,862	2.77%
32	ISOTRETINOIN	236,376	\$4,213,495	\$7,128,012	\$11,341,507	\$47.98	299,683	\$5,107,583	\$8,232,875	\$13,340,458	\$44.52	63,307	26.78%
33	TRANEXAMIC ACID	97,036	\$1,810,637	\$1,777,017	\$3,587,654	\$36.97	159,269	\$2,393,543	\$3,655,448	\$6,048,992	\$37.98	62,233	64.13%
34	DUPILUMAB	151,145	\$258,802,303	\$4,020,019	\$262,822,322	\$1,738.88	213,318	\$366,173,611	\$4,994,865	\$371,168,476	\$1,739.98	62,173	41.13%
35	BUDESONIDE + GLYCOPYRRONIUM + FORMOTEROL	68,245	\$5,229,924	\$585,144	\$5,815,068	\$85.21	126,392	\$9,038,148	\$1,040,856	\$10,079,004	\$79.74	58,147	85.20%

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.
 ** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.
 *** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

PBS Expenditure and Prescriptions 2023-24

Table 10(a): PBS Generic Prescriptions per ATC level 1, 2023-24

Section 85 and Section 100, excluding Efficient Funding of Chemotherapy items, including under co-payment prescriptions and Doctors' Bag

ATC Level 1 Group	Total Prescriptions	Total Prescriptions Generic Percentage*	Total Expenditure	Total Expenditure Generic Percentage
ATC - A: ALIMENTARY TRACT AND METABOLISM	51,046,567	62.7%	\$1,483,152,684	27.1%
ATC - B: BLOOD AND BLOOD FORMING ORGANS	12,862,297	24.7%	\$987,889,425	4.5%
ATC - C: CARDIOVASCULAR SYSTEM	106,587,868	80.4%	\$1,287,552,115	57.5%
ATC - D: DERMATOLOGICALS	5,525,628	66.4%	\$443,173,937	12.8%
ATC - G: GENITO URINARY SYSTEM AND SEX HORMONES	8,420,736	59.8%	\$314,754,192	22.9%
ATC - H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	6,964,357	90.9%	\$162,665,779	48.0%
ATC - J: ANTIINFECTIVES FOR SYSTEMIC USE	24,853,103	88.6%	\$1,476,629,989	10.8%
ATC - L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	4,829,774	44.9%	\$4,964,502,898	7.9%
ATC - M: MUSCULO-SKELETAL SYSTEM	11,622,414	64.9%	\$664,133,473	9.0%
ATC - N: NERVOUS SYSTEM	73,787,838	73.6%	\$1,550,095,044	40.8%
ATC - P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	111,627	3.7%	\$4,621,269	1.7%
ATC - R: RESPIRATORY SYSTEM	13,279,493	40.0%	\$1,286,197,648	8.9%
ATC - S: SENSORY ORGANS	10,575,573	24.1%	\$788,092,972	3.4%
ATC - V: VARIOUS	132,231	48.7%	\$27,370,799	30.7%

* % corresponds to the utilisation of generic medicines as a proportion of total utilisation for each ATC classification




Table 10(b): PBS Generic Prescriptions Percentage Share by ATC level 1, 2023-24

Section 85 and Section 100, excluding Efficient Funding of Chemotherapy items, including under co-payment prescriptions and Doctors' Bag

ATC Level 1 Group	Total Prescriptions Generic Percentage*	Total Expenditure Generic Percentage*
ATC - A: ALIMENTARY TRACT AND METABOLISM	13.9%	14.4%
ATC - B: BLOOD AND BLOOD FORMING ORGANS	1.4%	1.6%
ATC - C: CARDIOVASCULAR SYSTEM	37.3%	26.6%
ATC - D: DERMATOLOGICALS	1.6%	2.0%
ATC - G: GENITO URINARY SYSTEM AND SEX HORMONES	2.2%	2.6%
ATC - H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	2.8%	2.8%
ATC - J: ANTIINFECTIVES FOR SYSTEMIC USE	9.6%	5.7%
ATC - L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	0.9%	14.1%
ATC - M: MUSCULO-SKELETAL SYSTEM	3.3%	2.2%
ATC - N: NERVOUS SYSTEM	23.6%	22.7%
ATC - P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	0.0%	0.0%
ATC - R: RESPIRATORY SYSTEM	2.3%	4.1%
ATC - S: SENSORY ORGANS	1.1%	1.0%
ATC - V: VARIOUS	< 0.1%	0.3%
Total	100.0%	100.0%

* % corresponds to the utilisation of generic medicines as a proportion of total utilisation for all ATCs

Tables 10(a) and 10(b) Excludes non-therapeutic products (ATC V04 diagnostic agents, V06 general nutrients and V07 all other non-therapeutic products)

Table 11: PBS Prescriptions and Government Cost by Formulary, 2023-24

Section 85 and Section 100, including under co-payment prescriptions and Doctors' Bag

Formulary Group ¹	PBS Subsidised Prescriptions	Under co-payment Prescriptions	Total Prescriptions	Percentage	Government Cost	Percentage
F1	32,422,878	2,630,789	35,053,667	10.5%	\$11,043,429,933	62.2%
F2	183,548,412	102,766,361	286,314,773	86.1%	\$4,809,651,851	27.1%
Combination Drugs ²	10,450,227	599,168	11,049,395	3.3%	\$1,885,833,231	10.6%
Other ³	87,092	15,402	102,494	0.0%	\$3,606,642	0.0%
Total	226,508,609	106,011,720	332,520,329	100.0%	\$17,742,521,656	100.0%

Notes:

1. The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2. Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands. Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply. Allocation to F1 or F2 is determined by legislative instrument.
2. Combination Drugs are not allocated to any formulary.
3. The category 'Other' includes extemporaneously prepared items.

PBS Expenditure and Prescriptions 2023-24

Table 12(a): Top 20 Responsible Persons by Total Cost, 2023-24

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Doctors' Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)*	Total Cost**	Derived Ex-Manufacturer Sales ***
1	JANSSEN-CILAG PTY LTD	1,676,486	229,725	1,906,211	\$1,250,014,743	\$22,903,813	\$1,272,918,557	\$1,104,380,319
2	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,609,504	1,779,297	7,388,801	\$1,030,977,482	\$55,621,958	\$1,086,599,440	\$879,202,945
3	ABBVIE PTY LTD	2,088,535	393,794	2,482,329	\$906,774,983	\$21,758,991	\$928,533,974	\$846,079,796
4	APOTEX PTY LTD	42,880,532	21,309,249	64,189,781	\$650,299,350	\$221,914,765	\$872,214,115	\$348,547,423
5	BAYER AUSTRALIA LTD	3,657,825	551,718	4,209,543	\$664,607,516	\$46,285,630	\$710,893,145	\$599,403,358
6	SANDOZ PTY LTD	30,005,462	28,362,715	58,368,177	\$532,219,843	\$174,506,919	\$706,726,762	\$380,815,171
7	ASTRAZENECA PTY LTD	5,973,762	971,474	6,945,236	\$603,803,505	\$72,376,564	\$676,180,069	\$512,731,051
8	VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD.	30,054	-	30,054	\$635,486,482	\$409,144	\$635,895,626	\$489,841,613
9	ROCHE PRODUCTS PTY LTD	753,002	51,350	804,352	\$580,896,600	\$7,925,096	\$588,821,696	\$474,828,815
10	ALPHAPHARM PTY LTD	27,227,907	15,064,782	42,292,689	\$441,496,886	\$139,408,152	\$580,905,038	\$267,673,612
11	SANOFI-AVENTIS AUSTRALIA PTY LTD	4,790,675	1,873,049	6,663,724	\$538,878,719	\$35,607,805	\$574,486,524	\$435,445,149
12	BOEHRINGER INGELHEIM PTY LTD	8,623,843	1,564,321	10,188,164	\$420,869,968	\$85,143,969	\$506,013,937	\$375,721,283
13	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	3,510,830	301,339	3,812,169	\$443,453,086	\$48,786,626	\$492,239,712	\$414,710,730
14	PFIZER AUSTRALIA PTY LTD	2,481,118	1,152,810	3,633,928	\$457,038,972	\$26,165,497	\$483,204,469	\$423,425,653
15	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	3,661,198	537,009	4,198,207	\$417,069,854	\$57,572,470	\$474,642,324	\$341,980,983
16	AMGEN AUSTRALIA PTY LIMITED	1,423,870	45	1,423,915	\$456,477,099	\$15,903,305	\$472,380,404	\$377,068,733
17	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	4,097,081	364	4,097,445	\$411,213,681	\$41,147,015	\$452,360,697	\$365,645,518
18	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	427,192	2,360	429,552	\$432,663,353	\$5,297,842	\$437,961,195	\$393,948,161
19	ARROW PHARMA PTY LTD	19,667,946	8,864,825	28,532,771	\$335,396,280	\$95,363,414	\$430,759,693	\$191,025,807
20	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,227,313	698,691	5,926,004	\$274,095,729	\$50,253,249	\$324,348,979	\$193,913,592

* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

PBS Expenditure and Prescriptions 2023-24

Table 12(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2023-24

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Doctors' Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)*	Total Cost**	Derived Ex-Manufacturer Sales ***
1	APOTEX PTY LTD	42,880,532	21,309,249	64,189,781	\$650,299,350	\$221,914,765	\$872,214,115	\$348,547,423
2	SANDOZ PTY LTD	30,005,462	28,362,715	58,368,177	\$532,219,843	\$174,506,919	\$706,726,762	\$380,815,171
3	ALPHAPHARM PTY LTD	27,227,907	15,064,782	42,292,689	\$441,496,886	\$139,408,152	\$580,905,038	\$267,673,612
4	ARROW PHARMA PTY LTD	19,667,946	8,864,825	28,532,771	\$335,396,280	\$95,363,414	\$430,759,693	\$191,025,807
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	10,596,550	7,103,354	17,699,904	\$170,065,345	\$63,157,511	\$233,222,857	\$115,335,424
6	BOEHRINGER INGELHEIM PTY LTD	8,623,843	1,564,321	10,188,164	\$420,869,968	\$85,143,969	\$506,013,937	\$375,721,283
7	ASTRAZENECA PTY LTD	5,973,762	971,474	6,945,236	\$603,803,505	\$72,376,564	\$676,180,069	\$512,731,051
8	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,609,504	1,779,297	7,388,801	\$1,030,977,482	\$55,621,958	\$1,086,599,440	\$879,202,945
9	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,227,313	698,691	5,926,004	\$274,095,729	\$50,253,249	\$324,348,979	\$193,913,592
10	SANOFI-AVENTIS AUSTRALIA PTY LTD	4,790,675	1,873,049	6,663,724	\$538,878,719	\$35,607,805	\$574,486,524	\$435,445,149
11	ARROTEX PHARMACEUTICALS PTY LTD	4,751,608	1,200,047	5,951,655	\$147,337,235	\$44,704,430	\$192,041,664	\$127,184,384
12	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	4,097,081	364	4,097,445	\$411,213,681	\$41,147,015	\$452,360,697	\$365,645,518
13	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	3,661,198	537,009	4,198,207	\$417,069,854	\$57,572,470	\$474,642,324	\$341,980,983
14	BAYER AUSTRALIA LTD	3,657,825	551,718	4,209,543	\$664,607,516	\$46,285,630	\$710,893,145	\$599,403,358
15	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	3,510,830	301,339	3,812,169	\$443,453,086	\$48,786,626	\$492,239,712	\$414,710,730
16	SERVIER LABORATORIES (AUST.) PTY. LTD.	3,278,412	2,459,204	5,737,616	\$52,176,434	\$17,800,052	\$69,976,486	\$36,179,309
17	MUNDIPHARMA PTY LIMITED	2,930,486	320,887	3,251,373	\$126,504,131	\$21,324,042	\$147,828,173	\$89,081,274
18	VIATRIS PTY LTD	2,779,586	1,245,444	4,025,030	\$76,742,096	\$16,170,497	\$92,912,593	\$61,675,733
19	PFIZER AUSTRALIA PTY LTD	2,481,118	1,152,810	3,633,928	\$457,038,972	\$26,165,497	\$483,204,469	\$423,425,653
20	ABBVIE PTY LTD	2,088,535	393,794	2,482,329	\$906,774,983	\$21,758,991	\$928,533,974	\$846,079,796

* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

PBS Expenditure and Prescriptions 2023-24

Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2023-24

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Doctors' Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)*	Total Cost**	Derived Ex-Manufacturer Sales ***
1	APOTEX PTY LTD	42,880,532	21,309,249	64,189,781	\$650,299,350	\$221,914,765	\$872,214,115	\$348,547,423
2	SANDOZ PTY LTD	30,005,462	28,362,715	58,368,177	\$532,219,843	\$174,506,919	\$706,726,762	\$380,815,171
3	ALPHAPHARM PTY LTD	27,227,907	15,064,782	42,292,689	\$441,496,886	\$139,408,152	\$580,905,038	\$267,673,612
4	ARROW PHARMA PTY LTD	19,667,946	8,864,825	28,532,771	\$335,396,280	\$95,363,414	\$430,759,693	\$191,025,807
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	10,596,550	7,103,354	17,699,904	\$170,065,345	\$63,157,511	\$233,222,857	\$115,335,424
6	BOEHRINGER INGELHEIM PTY LTD	8,623,843	1,564,321	10,188,164	\$420,869,968	\$85,143,969	\$506,013,937	\$375,721,283
7	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,609,504	1,779,297	7,388,801	\$1,030,977,482	\$55,621,958	\$1,086,599,440	\$879,202,945
8	ASTRAZENECA PTY LTD	5,973,762	971,474	6,945,236	\$603,803,505	\$72,376,564	\$676,180,069	\$512,731,051
9	SANOFI-AVENTIS AUSTRALIA PTY LTD	4,790,675	1,873,049	6,663,724	\$538,878,719	\$35,607,805	\$574,486,524	\$435,445,149
10	ARROTEX PHARMACEUTICALS PTY LTD	4,751,608	1,200,047	5,951,655	\$147,337,235	\$44,704,430	\$192,041,664	\$127,184,384
11	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,227,313	698,691	5,926,004	\$274,095,729	\$50,253,249	\$324,348,979	\$193,913,592
12	SERVIER LABORATORIES (AUST.) PTY. LTD.	3,278,412	2,459,204	5,737,616	\$52,176,434	\$17,800,052	\$69,976,486	\$36,179,309
13	BAYER AUSTRALIA LTD	3,657,825	551,718	4,209,543	\$664,607,516	\$46,285,630	\$710,893,145	\$599,403,358
14	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	3,661,198	537,009	4,198,207	\$417,069,854	\$57,572,470	\$474,642,324	\$341,980,983
15	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	4,097,081	364	4,097,445	\$411,213,681	\$41,147,015	\$452,360,697	\$365,645,518
16	VIATRIS PTY LTD	2,779,586	1,245,444	4,025,030	\$76,742,096	\$16,170,497	\$92,912,593	\$61,675,733
17	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	3,510,830	301,339	3,812,169	\$443,453,086	\$48,786,626	\$492,239,712	\$414,710,730
18	PFIZER AUSTRALIA PTY LTD	2,481,118	1,152,810	3,633,928	\$457,038,972	\$26,165,497	\$483,204,469	\$423,425,653
19	UPJOHN AUSTRALIA PTY LTD	2,018,933	1,608,767	3,627,700	\$33,353,344	\$10,414,898	\$43,768,242	\$24,087,219
20	MUNDIPHARMA PTY LIMITED	2,930,486	320,887	3,251,373	\$126,504,131	\$21,324,042	\$147,828,173	\$89,081,274

* The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

*** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

Table 13: Number of PBS Approved Suppliers, 30 June 2024

Pharmacy State	Number of Community Pharmacies	Number of Private Hospitals	Number of Public Hospitals (Pharmaceutical Reforms)	Number of Dispensing Doctors
NSW	1,917	51	0	1
VIC	1,425	44	73	1
QLD	1,222	42	53	0
SA	471	11	15	1
WA	660	6	22	4
TAS	159	5	4	0
NT	43	1	6	0
ACT	80	6	0	0
Total	5,977	166	173	7

Table 14(a): PBS Brand Premiums, 2023-24

Section 85 and Section 100, excluding Doctors' Bag and including under co-payment prescriptions

	2023-24
Number of brands listed on the PBS ^(a)	5,159
Number of brands with a premium ^(a)	368
% of brands with a premium	7.1%
Average brand premium	\$7.12
Weighted average brand premium ^(b)	\$5.03
Brand premium range	\$0.44 to \$39.40
Prescriptions (millions) dispensed on the PBS ^(c)	187.8
Prescriptions (millions) dispensed with a brand premium	29.8
% of prescriptions dispensed with a brand premium	15.8%

Notes:

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2023 PBS Schedule. Note this differs from cover page figure which includes Doctors' Bag.

(b) Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium


(c) Includes only items where at least one brand is listed with a premium.

Table 14(b): Electronic PBS Prescriptions, 2023-24

Section 85 and Section 100, including under co-payment prescriptions and excluding Doctors' Bag

Prescription basis	PBS prescriptions	Percentage
Electronic Prescription	57,140,008	17.2%
Etp Prescription	163,422,786	49.2%
Paper-based Prescription	111,534,917	33.6%

Electronic prescriptions % in 2023-24



Prescription type notes:

A prescriber will write an Electronic Prescription, and the prescription information is sent to the National Prescription Delivery Service (NPDS);

The evidence of the Electronic Prescription is sent to the consumer as a unique electronic token (QR code) via SMS or email.

ETP is the safe and secure transfer of paper prescription information, between a prescriber and a community pharmacy;

using the NPDS and presents as a barcode (or sometimes a QR code) on the paper prescription and repeats.

Paper prescriptions are written by hand, or generated in clinical software, that is not connected to the NPDS.

Table 15(a): PBS/RPBS prescriptions dispensed by Community Pharmacies, 2023-24
 Section 85 and Section 100, excluding Doctors' Bag and under co-payment prescriptions

Prescription Type	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	40,815,928	21%	6,715,570	29%	910,935	13%	48,442,433	21%
Non-Discounted	155,401,252	79%	16,165,667	71%	6,055,431	87%	177,622,350	79%
Total	196,217,180	100%	22,881,237	100%	6,966,366	100%	226,064,783	100%

Table 15(b): PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2023-24
 Section 85 and Section 100, excluding Doctors' Bag and under co-payment prescriptions

Discount Range	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	39,801,050	97.5%	6,568,623	97.8%	885,662	97.2%	47,255,335	97.5%
\$0.50 - < \$1.00	634,568	1.6%	73,554	1.1%	15,130	1.7%	723,252	1.5%
< 50c	171,791	0.4%	44,217	0.7%	5,193	0.6%	221,201	0.5%
Other	208,519	0.5%	29,176	0.4%	4,950	0.5%	242,645	0.5%
Total	40,815,928	100.0%	6,715,570	100.0%	910,935	100.0%	48,442,433	100.0%

PBS Expenditure and Prescriptions 2023-24

Table 16(a): PBS/RPBS Medicines Supplied under Continued Dispensing by ATC Level 1 and Dispensing Pharmacy State, 2023-24

Section 85, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	22,335	15,240	10,700	3,462	5,742	3,600	165	1,459	62,703
ANTIINFECTIVES FOR SYSTEMIC USE	548	321	387	82	203	96	-	47	1,684
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	388	286	250	51	154	110	-	47	1,286
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	8	-	-	-	-	-	-	-	8
BLOOD AND BLOOD FORMING ORGANS	2,948	1,794	1,785	402	807	430	32	234	8,432
CARDIOVASCULAR SYSTEM	110,796	73,984	45,783	16,393	26,575	17,288	803	5,903	297,525
DERMATOLOGICALS	182	158	108	31	66	63	-	24	632
GENITO URINARY SYSTEM AND SEX HORMONES	2,995	2,265	1,590	689	999	987	35	292	9,852
MUSCULO-SKELETAL SYSTEM	1,584	1,003	1,013	230	516	375	7	154	4,882
NERVOUS SYSTEM	8,840	6,209	6,992	1,379	3,119	2,760	74	1,034	30,407
RESPIRATORY SYSTEM	6,211	4,392	3,612	1,280	1,628	1,645	37	462	19,267
SENSORY ORGANS	1,071	715	550	116	331	179	-	74	3,036
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	841	612	595	118	305	277	6	77	2,831
VARIOUS	25	13	8	-	-	14	-	-	60
Total	158,772	106,992	73,373	24,233	40,445	27,824	1,159	9,807	442,605

Table 16(b): PBS/RPBS Continued Dispensing Medicines Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2023-24

Section 85, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	\$792,626	\$540,963	\$375,774	\$122,243	\$206,269	\$130,181	\$6,809	\$50,108	\$2,224,972
ANTIINFECTIVES FOR SYSTEMIC USE	\$48,791	\$25,574	\$13,945	\$14,175	\$1,689	\$3,922	\$-	\$5,617	\$113,714
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$152,949	\$88,938	\$87,524	\$16,420	\$93,323	\$83,485	\$-	\$16,179	\$538,818
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$195	\$-	\$-	\$-	\$-	\$-	\$-	\$-	\$195
BLOOD AND BLOOD FORMING ORGANS	\$121,029	\$76,955	\$75,978	\$17,065	\$34,676	\$19,206	\$1,512	\$9,632	\$356,052
CARDIOVASCULAR SYSTEM	\$1,068,346	\$676,154	\$466,836	\$152,647	\$250,731	\$162,738	\$5,174	\$49,427	\$2,832,054
DERMATOLOGICALS	\$17,190	\$11,130	\$9,067	\$3,773	\$2,949	\$11,479	\$-	\$529	\$56,115
GENITO URINARY SYSTEM AND SEX HORMONES	\$20,461	\$13,073	\$11,597	\$3,076	\$6,564	\$5,564	\$97	\$1,882	\$62,312
MUSCULO-SKELETAL SYSTEM	\$24,188	\$13,655	\$13,504	\$3,998	\$5,943	\$4,002	\$99	\$2,352	\$67,740
NERVOUS SYSTEM	\$126,028	\$93,242	\$112,877	\$16,995	\$32,164	\$42,932	\$857	\$16,143	\$441,238
RESPIRATORY SYSTEM	\$187,880	\$126,446	\$95,458	\$32,010	\$48,664	\$46,648	\$1,160	\$12,750	\$551,016
SENSORY ORGANS	\$17,613	\$9,750	\$23,296	\$1,356	\$4,622	\$2,454	\$-	\$895	\$59,986
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$9,154	\$6,896	\$6,609	\$1,314	\$2,971	\$2,923	\$48	\$780	\$30,694
VARIOUS	\$6,458	\$2,638	\$1,448	\$-	\$-	\$1,466	\$-	\$-	\$12,010
Total	\$2,592,908	\$1,685,414	\$1,293,913	\$385,072	\$690,566	\$516,999	\$15,755	\$166,292	\$7,346,918

Notes:

Continued Dispensing Emergency Measures ended on 30 June 2022 (end of previous financial year). However between 22 December 2023 and 1 March 2024 a wider range of PBS medicines was available to temporarily support patients affected by the flooding disaster in Far North Queensland to continue to access their PBS subsidised medicines. Includes medicines listed under National Health (Continued Dispensing - Emergency Measures) Determination 2023, dispensed under ongoing or emergency measures. Small cells with counts less than 6 are suppressed and removed from the total.

PBS Expenditure and Prescriptions 2023-24

Table 17(a): Remuneration for Community Pharmacies and Friendly Societies¹ for PBS subsidised prescriptions, 2020-21 to 2023-24
Section 85 and Section 100, including Doctors' Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenditure for PBS and RPBS Prescriptions	2020-21	2021-22	2022-23	2023-24
Price to Pharmacists					
	Ex-Manufacturer Price	\$7,365,489,178	\$8,444,339,121	\$9,969,346,160	\$10,477,152,240
	Wholesale Mark-up	\$425,201,966	\$457,573,971	\$527,361,985	\$538,054,866
	Sub total	\$7,790,691,143	\$8,901,913,092	\$10,496,708,145	\$11,015,207,106
Administration, Handling and Storage Costs					
	AHI fee	\$1,125,904,411	\$1,159,674,289	\$1,252,469,303	\$1,337,103,022
	Sub total	\$1,125,904,411	\$1,159,674,289	\$1,252,469,303	\$1,337,103,022
Pharmacist's Specialised Skills in Dispensing the Medicines					
	Dispensing Fee	\$1,669,777,575	\$1,688,020,597	\$1,753,678,692	\$1,903,088,676
	Dangerous Drug Fee	\$40,655,693	\$41,333,062	\$44,304,924	\$54,813,885
	Wastage	\$4,301,110	\$6,337,018	\$6,872,742	\$4,552,629
	Container Fee	\$1,416,434	\$1,136,510	\$803,059	\$749,931
	Sub total	\$1,716,150,812	\$1,736,827,187	\$1,805,659,417	\$1,963,205,120
Other					
	Electronic Prescription Fee*	\$14,878,379	\$19,336,557	\$22,868,231	\$0
	Sub total	\$14,878,379	\$19,336,557	\$22,868,231	\$0
	*The EPF ceased on 1 July 2023				
Total²	\$10,647,624,745	\$11,817,751,124	\$13,577,705,096	\$14,315,515,249	

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	\$7,365,489,178	\$8,444,339,121	\$8,444,339,121	\$9,969,346,160
Wholesale cost	\$425,201,966	\$457,573,971	\$457,573,971	\$527,361,985
Pharmacy cost	\$2,856,933,602	\$2,915,838,032	\$2,915,838,032	\$3,080,996,952
Total	\$10,647,624,745	\$11,817,751,124	\$11,817,751,124	\$13,577,705,096

1. Table 17 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

* Includes Efficient Funding of Chemotherapy (EFC) items dispensed by community pharmacies and friendly societies from March 2021 (EFC excluded prior to this as the pricing components were not available in the PBS online claims data).

* Includes private and public hospital HSD claims dispensed by community pharmacies and friendly societies.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

2. Health's 2023-24 Annual Report lists the administered expenses for pharmaceutical benefits as \$18.0 billion. The difference between that figure and the total figure above is attributable to:

* the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and some s100 data for community pharmacy and friendly societies only (it excludes a number of smaller s100 programs, for example the Opiate Dependence Treatment Program and Remote Area Aboriginal Health Services Program).

* the annual report data is based on accrual figures, whilst the above data is cash basis;

* the annual report does not include patient contributions;

* the annual report data does not include the Electronic Prescription Fee;

* the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS, and

* the annual report also excludes the items in the footnote 1 above.

PBS Expenditure and Prescriptions 2023-24

Table 17(b): Pharmacy remuneration for PBS prescriptions by Formulary, 2020-21 to 2023-24
Section 85 and Section 100, including Doctors' Bag

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

		Expenditure for PBS and RPBS Prescriptions		2020-21	2021-22	2022-23	2023-24	
Price to Pharmacists	Ex-Manufacturer Price	F1		\$6,036,369,345	\$6,946,108,258	\$8,110,353,644	\$8,538,537,107	
		F2		\$2,881,278,847	\$3,173,963,892	\$3,339,567,848	\$3,329,693,792	
		Combination Drugs		\$1,058,400,126	\$1,102,082,150	\$1,672,420,254	\$1,662,465,351	
		Other		\$4,014,564	\$3,697,247	\$3,543,111	\$3,260,802	
	Wholesale Mark-up	F1		\$236,417,888	\$241,537,021	\$287,519,037	\$287,519,037	
		F2		\$204,825,038	\$239,096,429	\$248,407,660	\$243,196,830	
		Combination Drugs		\$41,695,718	\$44,437,621	\$59,057,346	\$60,455,527	
		Other		\$302,184	\$278,501	\$266,848	\$245,547	
		Sub total		\$10,463,303,710	\$11,751,201,120	\$13,721,135,749	\$14,125,373,993	
	Administration, Handling and Storage Costs	AHI fee	F1		\$249,038,681	\$272,201,643	\$318,792,298	\$342,930,454
		F2		\$1,229,080,643	\$1,271,522,895	\$1,325,307,185	\$1,410,124,080	
		Combination Drugs		\$53,617,781	\$55,670,930	\$68,582,471	\$75,804,976	
		Other		\$863,505	\$759,890	\$701,145	\$700,400	
		Sub total		\$1,532,600,610	\$1,600,155,358	\$1,713,383,099	\$1,829,559,910	
Pharmacist's Specialised Skills in Dispensing the Medicines	Dispensing Fee	F1		\$222,488,929	\$238,469,836	\$254,420,311	\$290,067,935	
		F2		\$2,087,912,846	\$2,148,448,113	\$2,241,620,716	\$2,405,619,216	
		Combination Drugs		\$83,218,259	\$84,256,809	\$80,517,066	\$92,147,900	
		Other		\$3,066,071	\$2,577,941	\$2,331,054	\$2,281,941	
	Dangerous Drug Fee	F1		\$9,877,147	\$12,407,721	\$15,429,993	\$19,791,423	
		F2		\$31,857,077	\$31,733,101	\$31,844,257	\$37,231,323	
		Combination Drugs		\$8,861,645	\$7,678,935	\$6,533,414	\$8,345,871	
		Other		\$5,611	\$4,931	\$4,182	\$1,782	
	Wastage	F1		\$1,295,191	\$1,366,619	\$1,659,047	\$1,849,537	
		F2		\$5,120,059	\$7,271,364	\$7,972,974	\$5,639,171	
		Combination Drugs		\$144,868	\$140,310	\$124,753	\$131,481	
		Other		\$2,450	\$2,376	\$2,261	\$3,230	
	Container Fee	F1		\$98,208	\$78,264	\$62,078	\$62,351	
		F2		\$2,818,452	\$2,272,087	\$1,672,427	\$1,638,323	
		Combination Drugs		\$31,371	\$21,050	\$12,484	\$12,349	
		Other		\$808	\$533	\$328	\$410	
		Sub total		\$2,456,798,993	\$2,536,729,989	\$2,644,207,346	\$2,864,824,243	
	Other	Electronic Prescription Fee	F1		\$1,861,291	\$2,528,850	\$3,072,477	\$0
			F2		\$20,257,621	\$26,339,081	\$30,939,918	\$0
		Combination Drugs		\$775,005	\$1,005,569	\$1,055,073	\$0	
		Other		\$35,776	\$50,976	\$65,785	\$0	
		Sub total		\$22,929,694	\$29,924,476	\$35,133,253	\$0	
	<small>*The EPF ceased on 1 July 2023</small>							
	Total²			\$14,475,633,007	\$15,918,010,943	\$18,113,859,447	\$18,819,758,146	

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	F1	\$6,036,369,345	\$6,946,108,258	\$8,110,353,644	\$8,538,537,107
	F2	\$2,881,278,847	\$3,173,963,892	\$3,339,567,848	\$3,329,693,792
	Combination Drugs	\$1,058,400,126	\$1,102,082,150	\$1,672,420,254	\$1,662,465,351
	Other	\$4,014,564	\$3,697,247	\$3,543,111	\$3,260,802
	Sub total	\$9,980,062,882	\$11,225,851,548	\$13,125,884,858	\$13,533,957,051
Wholesale cost	F1	\$236,417,888	\$241,537,021	\$287,519,037	\$300,708,827
	F2	\$204,825,038	\$239,096,429	\$248,407,660	\$243,196,830
	Combination Drugs	\$41,695,718	\$44,437,621	\$59,057,346	\$60,455,527
	Other	\$302,184	\$278,501	\$266,848	\$245,547
	Sub total	\$483,240,828	\$525,349,572	\$595,250,891	\$604,606,732
Pharmacy cost	F1	\$484,659,448	\$527,052,933	\$593,436,203	\$654,701,700
	F2	\$3,377,046,698	\$3,487,586,642	\$3,639,357,478	\$3,860,252,113
	Combination Drugs	\$146,648,929	\$148,773,602	\$156,825,262	\$176,442,577
	Other	\$3,974,222	\$3,396,646	\$3,104,755	\$2,987,763
	Sub total	\$4,012,329,297	\$4,166,809,823	\$4,392,723,698	\$4,694,384,153
	Total	\$14,475,633,007	\$15,918,010,943	\$18,113,859,447	\$18,832,947,936

1. Table 17b is for PBS and RPBS prescriptions claimed by all pharmacies for both Section 85 and Section 100 items. It includes Government and patient contributions.

Given what data is and is not included, this table may not be directly comparable to other tables in this publication.

2. Health's 2023-24 Annual Report lists the administered expenses for pharmaceutical benefits as \$18.0 billion. The difference between that figure and the total figure above is attributable to:

- * the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and s100 data for all pharmacy types (it excludes a number of smaller s100 programs, for example the Opiate Dependence Treatment Program and Remote Area Aboriginal Health Services Program).
- * the annual report data is based on accrual figures, whilst the above data is cash basis;
- * the annual report does not include patient contributions;
- * the annual report data does not include the Electronic Prescription Fee;
- * the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS

Table 18: CPA Professional Pharmacy Programs Expenditure, 2023-24

Under the Seventh CPA there were a range of professional programs and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programs under the 7CPA in 2023-24 by relevant categories.

Program Type	Actual Expenditure
Rural Pharmacy Maintenance Allowance	\$37,326,000
Rural Pharmacy Workforce Program	\$4,436,500
Medication Management services	\$116,799,406
Medication Adherence services	\$137,966,681
Aboriginal & Torres Strait Islander programs	\$4,107,500
Pharmacy Program administration fees	\$8,517,551
Programs Total	\$309,153,638

Notes:

1. For the Programs administration arrangements for 2023-24 the total funding provided to the Pharmacy Programs Administrator (i.e Australian Healthcare Associates) was \$309,153,638. Of this, \$8,517,551 (GST excl) was provided to the Pharmacy Programs Administrator for the purpose of Pharmacy Program administration fees. This means the Pharmacy Programs Administrator administration fees was 2.76% of the total funds.

2. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 17 of the report.

3. Rural Pharmacy Workforce Program, Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

Rural Pharmacy Workforce Program consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$102,000
Emergency Locum Service	\$150,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$750,000
Undergraduate Pharmacy-Scholarship Scheme	\$743,000
CPE - Continuing Professional Education Allowance	\$350,000
Pharmacy - Rural Administration Support	\$380,000
Rural Pharmacy - Mentor Scheme	\$371,500
Post Intern Incentive Allowance	\$220,000
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$690,000
RPLO	\$680,000
Program Total	\$4,436,500

Medication Management services consist of the following elements:	Actual Expenditure
Diabetes Medscheck and Medscheck	\$60,479,500
Residential Medication Management Review (RMMR)	\$16,154,667
Home Medicines Review (HMR)	\$28,872,667
Quality Use of Medicines (QUM)	\$11,292,572
Program Total	\$116,799,406

Medication Adherence services consist of the following elements:	Actual Expenditure
Dose Administration Aids	\$104,782,500
Indigenous Dose Administration Aids	\$25,900,833
Staged Supply	\$7,283,348
Program Total	\$137,966,681

Aboriginal & Torres Strait Islander Programs consist of the following elements:	Actual Expenditure
Workforce (scholarships)	\$170,000
Workforce (traineeships)	\$71,000
Indigenous Health Services Pharmacy Support Program (IHSPS)	\$3,866,500
Program Total	\$4,107,500

Table 19: Actual Costs of Major Components of CPA*, 2023-24

Component	Expenditure
Pharmacy remuneration	\$3,080,996,952
Wholesale remuneration	\$527,361,985
Professional programs	\$309,153,638
Community Services Obligation (CSO)	\$225,000,000
Total	\$4,142,512,574

* The 7th Community Pharmacy Agreement(CPA) went from 1 July 2020 to 30 June 2024.

The 8th CPA began on 1 July 2024 and will go to 30 June 2029

Notes:

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programs and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Department of Health and Aged Care receives from Services Australia. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

Table 20: Community Services Obligation (CSO) Expenditure, 2023-24

Component	Expenditure
CSO funding pool	\$223,609,000
CSO admin	\$1,391,000
Total	\$225,000,000

Figures are rounded to the nearest \$1,000

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health and Aged Care.

PBS INFORMATION LINE REPORT, 2023-24

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1st July 2023 – 30th June 2024, the information line answered 7,055 calls. This was an increase of 2.32% from the previous financial year, where 6,895 calls were answered.

Breakdown of calls by month:

Month	Number of calls
Jul-23	640
Aug-23	636
Sep-23	742
Oct-23	658
Nov-23	671
Dec-23	442
Jan-24	561
Feb-24	622
Mar-24	547
Apr-24	568
May-24	518
Jun-24	450
Total	7,055

National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2021 until 30 June 2025.

The NDSS is managed by the Department of Health and Aged Care through the Diabetes Support and CSO Section, in the Pharmacy Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin pump consumables products, continuous glucose monitoring products, and blood and urine testing strips, and are available through NDSS Access Points nationally. Access Points mainly comprise community pharmacies plus a very small number of other entities, such as health centres, hospitals and aged care facilities. There are currently over 5,945 NDSS Access Points operating in Australia.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%
2017-18	403,307	1.7%	873,632	1.6%	1,276,939	1.7%
2018-19	416,269	3.2%	892,801	2.2%	1,309,070	2.52%
2019-20	438,365	5.3%	928,492	4%	1,366,857	4.4%
2020-21	443,572	1.19%	945,903	1.88%	1,389,475	1.65%
2021-22	466,014	5.1%	988,155	4.45%	1,454,169	4.7%
2022-23	466,481	0.10%	984,619	-0.36%	1,451,100	-0.21%
2023-24	481,336	3.18%	1,004,553	2.02%	1,485,889	2.04%

National Diabetes Services Scheme Expenditure

Total NDSS expenditure for products for the 2023-24 financial year was \$319M. From 2016-17, NDSS Registrant co-payments for subsidised products, are now returned to Consolidated Revenue.

Abbreviations

Abbreviation	Definition
ATC	Anatomical Therapeutic Classification
CPA	Community Pharmacy Agreement
CPI	Consumer Price Index
CSO	Community Services Obligation
CTG	Closing The Gap
DVA	Department of Veterans' Affairs
EFC	Efficient Funding of Chemotherapy
NDSS	National Diabetes Services Scheme
PBS	Pharmaceutical Benefits Scheme
RACF	Residential Aged Care Facility
RPBS	Repatriation Pharmaceutical Benefits Scheme
S100	Section 100
S85	Section 85

Technical Notes

Unless otherwise indicated this publication has been produced using data provided to the Department of Health and Aged Care by Services Australia. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by Services Australia. They refer only to paid services processed for prescriptions submitted and claimed via the PBS Online claiming system by approved suppliers. Claims of manually processed PBS programs are excluded.

From 2016-17 this publication is based on the date that a prescription medicine was supplied to a patient. Previous publications were based on the date that a claim was processed (and the payment finalised) by Services Australia. The historical data from 1948-49 to 2015-16 in Table 21(a) and Table 21(b) remains by date of processing.

Caution should be exercised in referring to the breakdown by patient category in Table 21(a) and Table 21(b), because of a past problem in supply data whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem was fixed from 2008-09 onwards, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

While Section 100 data has been included in the majority of tables in this report, this data does not include supplies to Remote Area Aboriginal Health Services with the exception of Tables 1(a) and 1(b) on page 2.

The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by financial year (based on date of supply); however, a few tables refer to Section 85 only and some tables report pharmacy program expenditure.

Expenditure on nusinersen and onasemnogene abeparvovec was adjusted to include manual payments that were not processed through the PBS Online system.

PBS data does not capture over-the-counter drugs, private prescriptions (non-PBS) or public inpatient prescriptions.

The Department of Health and Aged Care has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

Technical Notes and methodology: PBS Patient Co-Payment Reduction Estimated Savings

- General patient saving per script estimated based on the difference between the patient co-payment amount of \$31.60 and the amount payable had the patient co-payment amount not been reduced in 2023 and indexed in line with the CPI to \$48.10 from 1 January 2024. Figures rounded to the nearest dollar.
- Excludes \$1 discount, brand price premiums and special patient contributions.
- Excludes subsidised prescriptions for general patients with a lower patient co-payment, e.g.
 - patients eligible for the Closing the Gap PBS Co-payment program.
 - repeat supply of Efficient Funding of Chemotherapy medicines
- PBS data does not capture over-the-counter drugs, private prescriptions (non-PBS) or public inpatient prescriptions.
- Excludes concessional patients and RPBS.
- Patient savings in 2023 were estimated based on the difference between the patient co-payment amount of \$30.00 and the amount payable had the co-payment remained at \$42.50 in January 2023.
- Patient savings in 2024 were estimated based on the difference between the co-payment amount of \$31.60 and the amount payable had the patient co-payment amount not been reduced in 2023 and indexed in line with the CPI to \$48.10 in January 2024.
- Patient count is a count of unique general patients in the 2023-24 financial year.

Technical Notes and methodology: 60-day prescriptions and estimated savings

- Patient savings are estimated by calculating the difference between the average monthly patient contribution for 2 x 30-Day scripts compared to an equivalent 60-Day script for the corresponding period. The calculation includes 60-Day items used as 30-Day items (i.e., where the dispensed quantity was less than 56). The patient contribution is the actual patient contribution (including any pharmacy discounts), excluding any brand price premium.
- Estimated patient savings may be lower than previously reported due to the inclusion of pharmacy discounts in the calculation.
- Excludes RPBS prescriptions.

Technical Notes and methodology: reduced Safety Net threshold and estimated savings

- Both existing and new Safety Net patients benefitted from the reduction, with:
 - Existing patients reaching the Safety Net threshold sooner, and spending less compared to previous years
 - New patients able to reach the Safety Net where they have not been eligible in previous years
- The number of general patients accessing the PBS Safety Net reduced in 2023, as the PBS co-payment was reduced to \$30. This means that general patients are less likely to accumulate the total PBS expenditure required to reach the General PBS Safety Net.
- The PBS Safety Net accumulates over a calendar year and resets on 1 January every year, therefore patient savings data are calculated by calendar year. However, patient savings are reported on a financial year basis to align with this report.
- Patient savings were calculated as the difference between what would have been payable by individual patients had the PBS Safety Net threshold not been reduced compared to what they actually paid following the reduction in the Safety Net threshold in each calendar year.

General and concessional patient Safety Net threshold amounts from 2022 to 2024, and Safety Net threshold amounts had no reduction from 1 July 2022 occurred and Safety Net thresholds increased in line with Consumer Price Index

Calendar Year	Safety Net Threshold Start Date	Safety Net Threshold End Date	Patient Category	Safety Net Threshold	Safety Net Threshold in Line With CPI Had the 1 July 2022 Reduction Not Taken Place
2022	1-Jul-22	31-Dec-22	Concessional	\$244.80	\$326.40
2022	1-Jul-22	31-Dec-22	General	\$1,457.10	\$1,542.10
2023	1-Jan-23	31-Dec-23	Concessional	\$262.80	\$350.40
2023	1-Jan-23	31-Dec-23	General	\$1,563.50	\$1,654.70
2024	1-Jan-24	31-Dec-24	Concessional	\$277.20	\$369.60
2024	1-Jan-24	31-Dec-24	General	\$1,647.90	\$1,744.00

- Patient savings were calculated based on savings at the patient level for patients that reached the PBS Safety Net each year. Complete PBS Safety Net family structure data were not available for the calculation of savings resulting in the final figures likely over-estimating total savings.
 - Concessional patient savings calculated based on partial PBS Safety Net family data indicated that savings were over-estimated by an average of 26.4% across 2022-23 and 2023-24, compared to patient savings calculated at a patient level.
 - Therefore, the final reported figures for general patients are 73.6% of the patient savings estimated at a patient level. Due to the complexity of the adjustments required for estimating the general patient savings the family structure data could not be incorporated into this analysis.
- Patient savings were calculated differently for General and Concessional patients.

- Patient category was assigned to the last prescription for a patient within a calendar year.
- For concessional patients, it took 48 scripts for a concessional patient to reach the Safety Net threshold before the reduction. After the reduction it took 36 scripts, or 12 fewer scripts. To calculate the savings, the patient contribution that would have been payable for the first (up to) 12 free Safety Net scripts was calculated based on the concessional maximum patient contribution.
- For general patients, the number of additional scripts that would have been required to reach the higher Safety Net threshold amount was calculated, based on the amount the patient would have paid without the Safety Net discount. The savings were calculated as the difference between the estimated undiscounted amount and the actual discounted amount paid for the additional scripts.